ComputAgeBench: Epigenetic Aging Clocks Benchmark

Dmitrii Kriukov[*]
Skoltech[1], AIRI[2]
Dmitrii.Kriukov@skoltech.ru

Evgeniy Efimov[*]
Skoltech[1], AIRI[2]
Evgeniy.Efimov@skoltech.ru

Ekaterina Kuzmina
Skoltech[1], AIRI[2]
Ekaterina.Kuzmina@skoltech.ru

Anastasiia Dudkovskaia
Skoltech[1], HSE[3]
Anastasiia.Dudkovskaia@skoltech.ru

Ekaterina E. Khrameeva[†]
Skoltech[1]
E.Khrameeva@skoltech.ru

Dmitry V. Dylov[†]
Skoltech[1], AIRI[2]
D.Dylov@skoltech.ru

Abstract

The success of clinical trials of longevity drugs relies heavily on identifying integrative health and aging biomarkers, such as biological age. Epigenetic aging clocks predict the biological age of an individual using their DNA methylation profiles, commonly retrieved from blood samples. However, there is no standardized methodology to validate and compare epigenetic clock models as yet. We propose *ComputAgeBench*, a unifying framework that comprises such a methodology and a dataset for comprehensive benchmarking of different clinically relevant aging clocks. Our methodology exploits the core idea that reliable aging clocks must be able to distinguish between healthy individuals and those with aging-accelerating conditions. Specifically, we collected and harmonized 66 public datasets of blood DNA methylation, covering 19 such conditions across different ages, and tested 13 published clock models. Additionally, we compiled 46 separate datasets to facilitate the training of new aging clocks. We believe our work will bring the fields of aging biology and machine learning closer together for the research on reliable biomarkers of health and aging.
Code: https://github.com/ComputationalAgingLab/ComputAge
Dataset: https://huggingface.co/datasets/computage/computage_bench

1 Introduction

Longevity drugs (*a.k.a., geroprotectors*) appear to be on the brink of entering clinical practice to slow down or reverse the features of aging [1, 2]. The research community is yet to identify proper biomarkers of aging and rejuvenation that could be used as clinical trial endpoints instead of or in combination with observations on patient lifespans [3]. Biological age (BA) has been proposed as one of such surrogate biomarkers of aging, defined as a *generalized measure of human health* compared to the average health of individuals at a given age within a population [4, 5]. Thus, if an individual has a


Preprint. Under review.

Figure 1: ComputAgeBench: benchmarking various epigenetic aging clock models. For a dataset X, obtained by profiling DNA methylation at CpG sites in bulk blood samples, an aging clock model f is trained to distinguish healthy individuals from those with pre-defined aging-accelerating conditions.

biological age of 40 at the chronological age of 30, it is assumed that their overall health corresponds to that of an average 40-year-old in the population. This relationship can be concisely expressed as

$$B = C + \Delta\,, \tag{1}$$

where B represents biological age, C denotes chronological age (*i.e.*, time since birth), and Δ symbolizes BA *acceleration* (or deceleration, if negative).

In general, BA can be estimated from a set of biomarkers X with a model (algorithm) $f : X \to B$, also called an *aging clock*. However, BA is latent: it has no ground truth value that can be measured directly and then used to train an aging clock model f in a classical supervised fashion, making clock validation a nontrivial task [6]. This obstacle forces researchers to introduce various additional assumptions about the aging clock behavior [7–10], as well as to experiment with different machine learning models (including penalized linear regressions, such as ElasticNet, support vector machines, decision trees, transformer-based neural networks, *etc*. [10, 11]) and underlying types of data X [12–14]. The vast majority of aging clocks, though, rely primarily on DNA methylation data, also called *epigenetic* aging clocks [15–19]. Summarizing abundant discussions about a "good" mathematical description of BA in the literature [1, 10, 20], we elicited four of its defining properties, formalized as follows.

Let $X \in \mathbb{R}^p$, where p is the number of biomarkers in data, $B \in \mathbb{R}$, and $f : X \to B$. Given the aging acceleration $\Delta = B - C$, the following four properties hold:

1. B is expressed in the same time units as C;

2. Δ allows distinguishing between healthy individuals and individuals with aging-accelerating or decelerating conditions (AACs or ADCs), such as severe chronic diseases;

3. B helps to predict the remaining lifespan better than C does [20];

4. B helps to predict the time to onset of chronic age-related diseases (*e.g.*, the Alzheimer's) better than C does [20].

Garnered together, these properties motivated us to construct a benchmarking methodology for validating the potential biological age predictors. In property №1, the model f should output age values in a biologically meaningful range, comparable with a typical lifespan, *e.g.*, from 0 to 120 years for the humans. This property is trivial, but necessary to differentiate biological age from other possible aging scores. To investigate if a model f satisfies the 2nd property, we can define a panel of aging-accelerating (or decelerating) conditions and test if the predicted Δ allows distinguishing the individuals with an AAC/ADC from a healthy control group, according to an appropriate statistical test. To validate the compliance with the 3rd and the 4th properties, one also needs data on mortality and multi-morbidity. That is, the information about the timing of death or the onset of chronic age-related diseases, along with a prior measurement of a set of relevant biomarkers. It is important to note that such data are highly sensitive and are generally not publicly available.

DNA methylation (DNAm) is the most prevalent measurement employed in the construction of aging clocks [21]. From a chemical point of view, DNA methylation refers to a covalent modification of DNA nucleotides by the methyl groups [22]. Specifically, cytosine nucleotides (C) followed by guanine nucleotides (G), also referred to as cytosines in a CpG context or simply CpG sites

2

(CpGs), are methylated most often in the mammalian cells, making it the most well-studied type of DNA methylation [23] (refer to Figure 1 for visualization of the DNA and CpGs). This epigenetic modification plays a crucial role in regulating gene expression and is engaged in a variety of cellular events, varying significantly across different species, tissues, and the lifespan. DNA methylation levels per site are usually reported quantitatively as beta values that represent the methylation proportion at a specific CpG site in the range from 0 to 1, where 0 indicates no methylation, and 1 indicates complete methylation across all the cells in the sample (Figure 1).

Importantly, despite the numerous recent publications of various aging clocks [4, 10, 21], including the ones built on DNA methylation, no systematic open-access benchmark, which would include a standardized panel of datasets, diseases, interventions, or other conditions, has been proposed to date to validate the aforementioned properties. In this paper, we introduce such a benchmark to validate the 1st and the 2nd properties in epigenetic aging clocks. To do this, we developed a methodology for identifying aging-accelerating conditions, which relies on simple, yet strict and evidence-based principles for defining and selecting a panel of aging-accelerating conditions. We collected an unprecedented number of DNA methylation datasets for the respective conditions from dozens of published studies. 66 of these datasets are intended for clock benchmarking, while the other 46—to facilitate the training of new epigenetic clocks. We also developed a cumulative benchmarking score that aggregates two error-based tasks and two simple, but informative tasks based on common statistical tests. Ultimately, this cumulative score enables comparing aging clock ability to satisfy the 1st and the 2nd properties stated above.

To demonstrate our methodology in a clinically relevant scenario, we specifically focused on the blood-, saliva-, and buccal-based epigenetic biomarkers obtained via a microarray-based technology. Such biomarkers are widespread in clinical testing and aging clock construction [10, 24]. We then examined 13 published epigenetic clocks and provided their benchmarking results.

2 Related work and Background

2.1 Aging clock construction methodology

Because the BA ground truth values cannot be measured, and, therefore, a direct validation of aging clocks is problematic, previous studies introduced various approaches to construct aging clocks with different underlying assumptions. The most widespread one, belonging to the so-called "first-generation aging clocks", uses an assumption that a model f can be trained to predict chronological age, *i.e.*, $C = \hat{C} + \varepsilon = f(X) + \varepsilon$, and its predictions will correspond to BA: $B = \hat{C}$. The simplicity of this approach has made it attractive for decades, and it is still used today to train new aging clocks on new types of data [25–29]. In fact, BA obtained by this approach can satisfy the 2nd [8] and the 3rd [30] properties from our definition. However, using this assumption in Eq. (1) leads us to the conclusion that $\varepsilon = -\Delta$. It then turns out that the perfect solution of the chronological age prediction problem, *i.e.*, minimizing the prediction error so that $\varepsilon \to 0$, leads to the inability of a clock to identify any aging acceleration or deceleration. Namely, it implies that $\Delta \to -0$, which is also known as *the biomarkers paradox* [7, 31] (refer to Sluiskes et al. [6] for a more recent review). Supporting this concept, it has been shown that the clocks featuring strong correlation with the chronological age poorly correlate with the population mortality [32] (hence they fail to satisfy the 3rd property). As a consequence, validating clock performance in terms of accuracy of chronological age prediction becomes meaningless, because high accuracy may not necessarily correspond to a biologically relevant clock. Despite the obvious methodological challenges of this approach, the vast majority of aging clocks belong to the first generation [6].

Seeking for a better solution, researchers experimented with survival models, which led to the development of "second-generation aging clocks". In this approach, models are trained to predict time to death [16, 17, 33], and the resulting prediction is rescaled to age units to represent BA, therefore addressing the 3rd and the 4th properties of a "good" BA estimator. However, there is no open large-scale DNA methylation data containing time-to-death or multi-morbidity measurements, with existing studies being either available upon an authorized request or being held completely private (see Appendix A.8).

3

2.2 Attempts to compare epigenetic aging clocks

Despite reported attempts to compare the performance of different aging clocks, a benchmark with a standardized panel of datasets, diseases, interventions, or other conditions has not been proposed yet. As a result, different comparative studies employ widely varying validation data and approaches [1, 19, 30, 34–40]. As highlighted in a recent review on biomarker validation by Moqri et al. [1], "*for a reliable comparison across studies, . . . biomarker formulations should be established 'a priori' and not be further modified during validation*". In the same line of thought, we propose to define a standardized and a justified procedure for clock benchmarking *before* constructing any predictive model.

Two approaches we propose as essential tasks in our benchmark entail related prior art. For example, Porter et al. [41] and Mei et al. [34] used one-sample or two-sample aging acceleration tests for clock validation. Ying et al. [19] employed two-sample tests across multiple aging clocks. These authors implicitly tested the 2nd property of "good" aging clocks discussed above. Likewise, there were also attempts to test the 3rd and the 4th properties separately. In some works, including the recently updated pre-print of Biolearn [42], a Python-based framework for clock training and testing in ongoing development, authors performed Cox Proportional Hazards analysis and calculated hazard ratios with statistical significance to test if BA estimates of selected clocks are capable of predicting all-cause mortality or the onset of age-related diseases (*e.g.*, cardiovascular events) [30, 35–37, 40, 42]. However, these prior studies are either small-scale in terms of tested diseases [19], limited to predicting the chronological age only [38], lack standardized procedures for selecting data and conditions for clock comparison and compare only a small number of models [34, 41], or rely on mortality and disease data that are under restricted access [42]. Therefore, while developing our methodology, we attempted to mitigate all mentioned drawbacks, while balancing between framework simplicity, open source, and clinical relevance.

3 Benchmarking Methodology

An infographic overview of the proposed benchmarking of aging clocks is shown in Figure 2.

3.1 Criteria for selecting aging-accelerating conditions

In the context of clock benchmarking, we propose to define an aging-accelerating condition (AAC) as a biological condition that satisfies the following three criteria (Figure 2B). First, having an AAC must lead to decreased life expectancy (LE) compared to the general population, even when treated with existing therapies. Second, an AAC must be chronic (to safely assume that it has sufficient time to drive observable changes in DNAm). And third, an AAC must manifest systemically, so that it can be expected to affect DNAm in blood, saliva, and buccal cells (hereafter referred to as BSB).

Importantly, the decrease in LE and the corresponding increase in mortality must result mainly from intrinsic organismal causes rather than from socioeconomic factors and self-destructive behaviors related to a given condition. The second criterion is aimed at excluding short-term conditions such as acute infectious diseases, stressful events, and other confounding DNAm-alternating accidents, whose effects might not induce significant changes in DNAm data obtained from BSB, or, on the contrary, might last too briefly to be reliably detected. The third part of the AAC definition precludes us from considering events with long-lasting and life-threatening consequences that might be difficult to observe in BSB-derived data. For instance, a bone fracture (unless it is a critical bone marrow reserve) or some types of malignances.

Conversely, an aging-decelerating condition (ADC) is defined as a condition that increases LE, compared to the general population, and features the same second and third criteria as an AAC. With human data, however, the ADCs are difficult to determine, as the human lifespan-increasing interventions are yet to emerge. To avoid ambiguous interpretation, we omitted such conditions in our benchmarking of human aging clocks (see Appendix A.4 and Table A1 for more details).

3.2 Criteria for dataset selection

Aiming to provide a comprehensive, easily accessible, and clinically relevant toolbox for the ongoing research on human epigenetic clocks, we relied on the following five criteria while performing the

4

Figure 2: ComputAgeBench methodology. A) The proposed pipeline for constructing aging clocks features an important step of validating the model on pre-defined aging-acceleration conditions that satisfy criteria (B) and are collected into datasets that meet criteria (C) for individual study design. D) Major classes that include putative aging-accelerating conditions. E) Aggregated dataset panel for benchmarking aging clocks, comprising 66 unique data sources (labeled by their Gene Expression Omnibus dataset identification numbers and conditions) from more than 50 studies. See Table A1 for the full names and Table A2 for the population-based evidence for including each condition.

datasets aggregation (Figure 2C). *First*, all datasets in the benchmark must feature *open access to pre-processed data*, without any data access requests or raw data processing required. *Second*, we only used data obtained from the BSB samples. *Third*, chronological ages must be annotated with, at most, one-year intervals (*e.g.*, without age binning by decades), including only samples from the age range of 18–90 years[1]. The only exception to this requirement are the individuals with certain *progeroid* conditions, such as the Hutchinson-Gilford progeria syndrome, who survive approximately 12 to 13 years on average: their pathologies resemble premature aging so strikingly [43] that we included patients aged under 18 years into the benchmark. *Fourth*, we employ data obtained only with the Illumina Infinium BeadChip (27K, 450K, and 850K) methylation microarrays, as they remain to be the most popular technologies for human DNAm profiling and clock construction. *Fifth*, we applied thresholds of at least 10 samples per dataset, 5 samples with an AAC per dataset, and 10 samples with an AAC across all datasets to attain sufficient statistical power.

---

[1]Reporting increased or decreased biological age for people outside of this range is debatable.

3.3 Collecting AAC datasets for benchmarking

To cover as many organismal systems affected by age-related conditions as possible, we split the aggregated data into nine broad categories (Figure 2D): cardiovascular diseases (CVD), immune system diseases (ISD), kidney diseases (KD), liver diseases (LD), metabolic diseases (MBD), musculoskeletal diseases (MSD), neurodegenerative diseases (NDD), respiratory diseases (RSD), and progeroid syndromes (PGS). In each class, we identified several AACs relying on the established lists of age-related diseases and on the leading causes of death [34, 44, 45], including closely associated conditions and other conditions mentioned in a variety of epigenetic clock studies [8, 16, 19, 34, 46]. The corresponding AACs with their abbreviations and population-based evidence for their inclusion are provided in Appendix (Tables A1 and A2, respectively).

Dataset search was performed using the NCBI Gene Expression Omnibus (GEO) database, an *omics* data repository with unrestricted access (`https://www.ncbi.nlm.nih.gov/geo/`). We applied filters to include the *Homo sapiens* species and all types of methylation-related studies (methylation microarray data can be found in any of these study types): methylation profiling by single-nucleotide polymorphism (SNP) array, methylation profiling by array, methylation profiling by genome tiling array, and methylation profiling by high throughput sequencing.

Upon performing the dataset search, only a portion of AACs from seven condition classes were retained (see Appendix and Table A2). All five dataset selection criteria were met by none of the found kidney- and liver-related AAC datasets, and by no buccal-based dataset. The resulting list of 66 datasets [47–96] comprises 65 blood studies and 1 saliva study, and is visualized in Figure 2E. An overview of all datasets, dataset sizes, and their age distributions is provided in Figure A1. Descriptive statistics for all datasets are provided in Figure A2.

We unified the metadata of all datasets by retrieving only the relevant metadata columns and formatting them into the appropriate data types, similarly to what was proposed by Ying et al. [42]. We also added the condition and condition class annotation, thus obtaining a single metadata file with 10,410 rows (samples) and the following columns: SampleID, DatasetID (dataset GEO accession number), PlatformID (sequencing platform), Tissue (blood or saliva), CellType (whole blood or cell type after sorting), Gender, Age, Condition, and Class (see also Appendix A.10 for details on data processing).

3.4 Epigenetic age predictors

Any epigenetic aging clock that predicts BA in age units (or can be re-scaled to them) can be validated in our benchmark. We tested 13 publicly available epigenetic clock models trained on adult human data to evaluate sample age (Table A3), with the model coefficients retrieved from the corresponding studies. Among the collected first-generation clocks, 6 were trained purely on blood samples [15, 19, 97, 98], 3 models were trained on multiple tissues [8, 32, 46]. Among the second-generation clocks, all were blood-based, and 2 models relied entirely on CpG sites as predictive features [16, 99], while the other 2 required additional information about gender and chronological age as inputs [17, 100]. Because the clocks were trained on somewhat differing data, some clock CpGs may be lacking in the datasets outside of training, so it is an established practice to impute such missing values [42, 101, 102]. We performed this imputation by employing the "gold standard" beta values averaged for each CpG site, retrieving them from the R "SeSAMe" package [103] (for the results on comparing imputation methods, see Appendix A.7). We also ensured that no data in the benchmark was used to train any of the selected clocks, and that all clock input and output structures were consistent with each other ("harmonized", as described by Ying et al. [42]).

3.5 Benchmarking tasks for evaluating aging clocks

To benchmark aging clock models, we propose four tasks: relative aging acceleration prediction (Figure 3A), absolute aging acceleration prediction (Figure 3B), chronological age prediction accuracy (Figure 3C), and systematic chronological age prediction bias (Figure 3D). In the first two tasks, the clocks are tested if they can correctly predict aging acceleration in the predefined panel of AAC datasets.

In the relative aging acceleration prediction task (AA2 task), we test aging clock ability to distinguish AAC from healthy control (HC) samples in a dataset containing both sample groups. After predicting ages in each dataset corresponding to this task using various clock models, we apply a two-sample

6

Welch's test per dataset and calculate a one-sided P-value (*i.e.*, $H_A : \Delta_{AAC} > \Delta_{HC}$) to determine if mean aging acceleration in the AAC cohort is significantly greater than that in the HC cohort (Figure 3A). Next, we apply the Benjamini-Hochberg correction procedure for controlling the false discovery rate (FDR) of predictions across all datasets, with an adjusted P-value less than 0.05 considered indicative of statistical significance. We selected a parametric test due to the assumption of normal distribution of Δ, a fundamental trait of multivariate linear regression models commonly used in aging clock construction.

In the absolute aging acceleration prediction task (AA1 task), we test clock ability to correctly predict positive aging acceleration for an AAC in the absence of the HC cohort. For each dataset in this task, we predict ages using various clock models, apply a one-sample Student's t-test and calculate a one-sided P-value (*i.e.*, $H_A : \Delta_{AAC} > 0$) to determine if mean aging acceleration in the AAC cohort is significantly greater than zero (Figure 3B). As before, we apply the Benjamini-Hochberg correction procedure for controlling FDR with the same adjusted P-value threshold.

Clearly, the first task (AA2) provides a more rigorous way to test aging clocks compared to AA1, because it helps to control potential covariate shifts, but the second task (AA1) deserves its place in the list, as it allows introducing more data to mitigate data scarcity.

The third task is aimed at distinguishing good predictors of chronological age from predictors of biological age. Due to the paradox of biomarkers mentioned above, it is highly unlikely that the same model could combine both these properties. Yet, the good predictors of chronological age are believed to be useful in forensics [104] or data labeling, where the chronological age information is lacking. We chose median absolute aging acceleration ($Med(|\Delta|)$), a full equivalent of median absolute error, for testing clock performance. We calculate it across HC samples from the whole dataset panel and report it as a single number expressed in years.

We introduced the fourth task, a prediction bias task, to evaluate the robustness of a given aging clock model to covariate shift between the original clock training dataset and the datasets from the proposed benchmark. Covariate shift, also referred to as batch effect in bioinformatics, denotes the shift between covariate distributions in two datasets. For instance, the distribution of methylation values for a given CpG site could be centered around 0.45 in one dataset and around 0.55 in the other one—a common scenario in DNAm and other omics data. Because each clock is trained on healthy controls, we expect age deviation of HC samples to be zero on average (*i.e.*, $E(\Delta_{HC}) = 0$). In practice, however, due to the presence of a covariate shift between the training and testing data, a clock might produce biased predictions, resulting in a systemic bias and adding or subtracting extra years for a healthy individual coming from an external dataset. The goal of the fourth task is to control for such systemic bias in clock predictions. Therefore, as a benchmarking metric for this task, we calculated median aging acceleration ($Med(\Delta)$) across HC samples from the entire dataset panel, which reflects the systematic shift in clock predictions caused by differences between datasets.

3.6 Cumulative benchmarking score

We define cumulative benchmarking score such that it would account for the main drawback of AA1 task, namely, the sensitivity to positive model bias. Let S_{AA2} denote total score of a model in AA2 task and S_{AA1} from the AA1 task (both S_{AA2} and S_{AA1} represent the number of datasets evaluated correctly by a model in the respective task), then the cumulative benchmarking score is:

$$BenchScore = S_{AA2} + S_{AA1} \cdot \left(1 - \frac{\max(0, Med(\Delta))}{Med(|\Delta|)} \right). \tag{2}$$

Consequently, if a model is positively biased, its performance in the AA1 task will be penalized by the bracketed coefficient by the S_{AA1}, the largest when the model bias $Med(\Delta)$ is zero. Because $Med(\Delta) \leq Med(|\Delta|)$, this coefficient is limited to the $[0, 1]$ interval.

While designing our metric, we aimed for simplicity and interpretability. At the same time, we sought to include more data in the benchmark to address data scarcity caused by the underrepresentation of certain AACs. Admittedly, there could be a more optimal solution for the metric, but we also believe that such a consensus solution must be proposed by a continuous collaborative discussion between the aging clock and machine learning communities, which we are eager to establish.

E Age acceleration two sample test (AA2) results

Model	CVD	ISD	MBD	MSD	NDD	PGS	RSD	Total
PhenoAgeV2	0/3	7/10	0/4	3/6	6/12	1/3	3/4	20/42
GrimAgeV2	0/3	7/10	0/4	1/6	2/12	2/3	2/4	14/42
GrimAgeV1	0/3	7/10	0/4	1/6	2/12	2/3	2/4	14/42
PhenoAgeV1	0/3	5/10	0/4	2/6	0/12	1/3	1/4	9/42
YingCausAge	0/3	4/10	0/4	0/6	1/12	1/3	0/4	6/42
YingAdaptAge	0/3	3/10	0/4	0/6	1/12	1/3	0/4	5/42
Lin	0/3	4/10	0/4	0/6	0/12	0/3	1/4	5/42
HorvathV2	0/3	4/10	0/4	0/6	0/12	1/3	0/4	5/42
HorvathV1	0/3	3/10	0/4	0/6	0/12	0/3	0/4	3/42
Zhang19_EN	0/3	1/10	0/4	0/6	0/12	1/3	0/4	2/42
Hannum	0/3	1/10	0/4	0/6	0/12	0/3	0/4	1/42
VidalBralo	0/3	0/10	0/4	0/6	0/12	0/3	0/4	0/42
YingDamAge	0/3	0/10	0/4	0/6	0/12	0/3	0/4	0/42

F Age acceleration one sample test (AA1) results

| Model	CVD	ISD	MBD	MSD	NDD	Total
GrimAgeV2	3/3	9/9	2/2	2/5	4/5	20/24
Zhang19_EN	0/3	9/9	1/2	5/5	4/5	19/24
Hannum	1/3	9/9	2/2	2/5	3/5	17/24
GrimAgeV1	1/3	9/9	2/2	2/5	1/5	15/24
VidalBralo	1/3	9/9	1/2	1/5	1/5	13/24
HorvathV2	0/3	9/9	0/2	0/5	3/5	12/24
HorvathV1	0/3	7/9	1/2	2/5	2/5	12/24
YingAdaptAge	1/3	4/9	1/2	2/5	3/5	11/24
Lin	0/3	8/9	0/2	0/5	1/5	9/24
PhenoAgeV2	0/3	5/9	1/2	2/5	1/5	9/24
PhenoAgeV1	0/3	6/9	0/2	0/5	1/5	7/24
YingDamAge	0/3	5/9	1/2	0/5	0/5	6/24
YingCausAge	0/3	2/9	0/2	0/5	0/5	2/24

Figure 3: ComputAgeBench tasks and performance of aging clock models. A-D) The four benchmarking tasks. (C) illustrates that chronological age prediction accuracy is measured by median absolute error $Med(|\Delta|)$ across all predictions. For a limiting case of prediction bias sketched in (D), all samples were predicted with positive age acceleration, leading to a strictly positive value of $Med(\Delta)$, graphically represented as a red arrow pointing to a cross. E) AA2 task results split into columns by condition class, where scores demonstrate the number of datasets per class in which a given clock model detected significant difference between the HC and AAC cohorts. F) AA1 task results: same as (E), but the statistics are calculated for datasets containing the AAC cohort alone.

3.7 Collecting HC datasets for training

To facilitate the ML community's engagement in developing reliable aging biomarkers, we applied our methodology to collect and unify the pre-processed datasets of HC patients, suitable for training novel aging clocks. This training data comprise 46 distinct datasets [102, 105–146] encompassing 7,419 DNA methylation profiles (see Figure A3) with annotated chronological ages. These datasets enable the training of first-generation aging clocks and the evaluation of various model architectures to determine those which best satisfy the aforementioned properties №1–4, thereby achieving superior performance on the proposed benchmark.

4 Results

The most rigorous of the four, AA2 task demonstrates that second-generation clocks (PhenoAgeV2 [99], GrimAgeV1 [17], GrimAgeV2 [100], and PhenoAgeV1 [16]) appear on top, particularly at predicting aging acceleration for the ISD class (Figure 3E, Supplementary Material Figure A6). Nevertheless, all clocks failed to detect aging acceleration in patients with cardiovascular and metabolic diseases, at least at the statistically significant level (see Figures A4 and A5 for results without FDR correction). Modest scores (<50% datasets in total) on the AA2 task across all models are expected, as no clocks had specifically been calibrated to pass this benchmarking task (and not a single first-generation clock had been trained to predict anything aside from chronological age).

In contrast, the first-generation aging clocks by Zhang et al. [32] and Hannum et al. [15] populated the top of the AA1 leaderboard, in addition to the GrimAge, exhibiting good scores across multiple condition classes (Figure 3F, Supplementary Material Figure A7). Notably, combining the results

Table 1: Benchmarking results.

Model name	AA2 score	AA1 score	$Med(|\Delta|)$, years	$Med(\Delta)$, years	$BenchScore$
PhenoAgeV2	**20**	9	7.6 ±0.1	-2.6 ±0.1	**29.0**
GrimAgeV1	14	15	7.5 ±0.1	5.7 ±0.1	17.4
PhenoAgeV1	9	7	8.0 ±0.1	-4.2 ±0.2	16.0
GrimAgeV2	14	20	9.8 ±0.1	9.3 ±0.1	15.1
HorvathV1	3	12	5.4 ±0.1	-0.1 ±0.1	15.0
HorvathV2	5	12	**4.1 ±0.1**	1.1 ±0.1	13.9
VidalBralo	0	13	9.1 ±0.1	0.1 ±0.2	12.8
Lin	5	9	7.5 ±0.1	2.1 ±0.2	11.4
YingAdaptAge	5	11	20.0 ±0.2	12.5 ±0.5	9.1
YingCausAge	6	2	9.0 ±0.1	1.3 ±0.2	7.7
YingDamAge	0	6	19.5 ±0.3	-14.5 ±0.5	6.0
Zhang19_EN	2	19	10.5 ±0.2	9.6 ±0.2	3.7
Hannum	1	17	7.5 ±0.1	6.3 ±0.1	3.7

of this task with the model bias task exposes the potential source of the exceptional "robustness" in predicting accelerated aging in datasets without healthy controls.

The task of chronological age prediction accuracy reveals two undeniable leaders (Table 1): HorvathV2 [46] and HorvathV1 [8] clocks, specifically tuned for this task on large multi-tissue datasets. Notably, clocks predicting chronological age with $Med(|\Delta|) \geq 18$ years would be inferior to a constant model yielding a 50 y.o. prediction (average age across all HC samples in the benchmark). Unless scaled, such clocks can hardly be used for inferring age acceleration.

Finally, to prove the validity of AA1 performance, a clock should also pass the task for being unbiased. We show that the AA1 leader, GrimAgeV2 clock [100], is also characterized by a large prediction bias for the HC samples (Table 1), warning us against considering its AA1 task score reliable. On the other hand, the top-2 unbiased HorvathV1 clock [8] and VidalBralo clock [98] have low prediction bias, rendering their AA1 performance as more trustworthy.

To account for the discrepancies of AA1 task interpretation regarding the prediction bias, we devised *cumulative benchmarking score* (Table 1) which penalizes AA1 score by the magnitude of prediction bias (see Eq. 2). With such a metric, a second-generation aging clock PhenoAgeV2 [99] becomes the most robust model in terms of distinguishing individuals with aging-accelerating conditions from the healthy cohort. This model is a leader, according to the cumulative benchmarking score and the AA2 task score. Closely behind it are the other second-generation clocks: GrimAgeV1 [17], PhenoAgeV1 [16], and GrimAgeV2 [100]. On the other hand, our results indicate that even the classic first-generation aging clocks, such as HorvathV1 [8] and HorvathV2 [46], can perform quite reliably in predicting biological age, at least for some condition classes. It is noteworthy that in both AA1 and AA2 tasks, many aging clocks perform well in detecting accelerated aging caused by immune system diseases, mostly represented by the human immunodeficiency virus (HIV) infection in our dataset, while the other disease classes are only captured by *some* clocks, putatively indicating that the models could have been implicitly and unintentionally trained to recognize only a certain subset of diseases. By providing a full decomposition of our benchmarking metrics in Figures 3E,F and Table 1, we strived to clarify such skewness towards particular condition classes and allow for a detailed examination of each clock's performance. Our analysis generalizes previous findings [34] and shows that comprehensive benchmarking of aging clocks can resolve the controversy regarding their robustness and utility.

5 Discussion

Biological age is an elusive concept that cannot be measured and validated directly, which necessitates careful choice of model assumptions to avoid methodological errors and false discoveries while estimating it. While maintaining some degree of correlation between predicted and chronological age is desirable, the biomarkers paradox [7] precludes one from automatically considering BA evaluation

via the classic performance metrics of chronological age prediction accuracy as acceptable. From a methodological perspective, training BA predictors to estimate time to death or to a disease onset remains the most rigorous approach to aging clock validation, as these events can be measured directly. However, obtaining such data is challenging due to various ethical and financial constraints. At present, no open-access data of DNA methylation annotated with either mortality or disease onset labels are available for public clock benchmarking (see Appendix A.8).

While mortality data remain unavailable, we propose to validate clocks by their ability to demonstrate BA acceleration *in a fixed pre-determined panel of datasets* for established aging-accelerating diseases or predict decelerated aging in the datasets of lifespan-prolonging interventions. For that, we developed our benchmark, where each aging clock could be tested across 4 distinct tasks. **We gathered an unprecedented number of DNA methylation datasets from 66 studies covering 19 putative aging-accelerating conditions and 46 more datasets of healthy individuals suitable for model training** to provide the ML community with a convenient entry point into the realm of aging biomarkers. Notably, no aging-decelerating conditions have been confirmed for the benchmark study (see Appendix A.4). It should be taken into account that *in vitro* cell reprogramming cannot serve as validation data for the deceleration effect, because, as has previously been shown [147], such data are essentially out-of-domain with regard to blood DNA methylation across aging.

To showcase our benchmark, we tested 13 different published models and revealed that second-generation aging clocks, namely, PhenoAge [16], GrimAge [17], and their upgraded variants [99, 100], appeared the most successful, according to the cumulative benchmarking score. As these clocks had initially been designed to predict all-cause mortality, they were expected to be robust in distinguishing aging-accelerating conditions. Yet, our findings reinforce the growing trends in training BA predictors based on mortality rather than on chronological age [1, 4].

As blood DNA methylation generally comes from the immune cells, which would be directly affected by the HIV, it is not surprising that the majority of clocks managed to discern accelerated aging in the immune system-related conditions (featured predominantly by the HIV infection in our dataset). This result supports the notion that the blood-based clocks might be implicitly attuned to such conditions, while only a few clocks are capable of successfully capturing accelerated aging in the other disease classes.

Remarkably, some datasets were evaluated incorrectly *by all models*, which may have several possible explanations apart from poor clock performance. First, a strong covariate shift between these data and the training data might impede model performance on some datasets. Second, some selected conditions might not induce accelerated aging in blood, either by itself or by the design of the original study (see Limitations in Appendix A.1). Third, the multidimensionality of aging as a biological phenomenon might not allow for correct prediction of all aging-accelerating conditions by such univariate measures as blood-based epigenetic clocks. In favor of this notion, it has recently been shown that different organ systems have different aging trajectories [148, 149], suggesting promising directions for future research outlined in Appendix A.2.

6 Conclusion

In this work, we developed the first systematic benchmark for evaluating epigenetic aging clocks. We believe it will help longevity researchers and data scientists to better gauge the power of existing biomarkers of aging, quantitatively assessing their role, limitations, and reliability. We anticipate that, as a result of such computational paradigm, rapid and reliable clinical trials of lifespan-extending therapies will become an attainable reality in a not-so-distant future.

7 Reproducibility statement

We assured the reproducibility of our pipeline by providing a Google Colab notebook (`https://colab.research.google.com/drive/1_nrGMUd8oH8ADNWUPNeXHr4ZAJlZOQhm`), which allows to download all datasets and benchmark all clocks considered in this article. Additionally, we provide a notebook (`https://colab.research.google.com/drive/17oODr9a5nz3GVV74Grxrxl1wxQ-Y0hAr`) that briefly outlines the methodology for constructing first-generation aging clocks based on our training dataset.

Acknowledgments and Disclosure of Funding

References

[1] Mahdi Moqri, Chiara Herzog, Jesse R Poganik, Kejun Ying, Jamie N Justice, Daniel W Belsky, Albert T Higgins-Chen, Brian H Chen, Alan A Cohen, Georg Fuellen, et al. Validation of biomarkers of aging. *Nature Medicine*, pages 1–13, 2024.

[2] Jamie N Justice, Laura Niedernhofer, Paul D Robbins, Vanita R Aroda, Mark A Espeland, Stephen B Kritchevsky, George A Kuchel, and Nir Barzilai. Development of clinical trials to extend healthy lifespan. *Cardiovascular endocrinology & metabolism*, 7(4):80–83, 2018.

[3] Nicholas J Schork, Brett Beaulieu-Jones, Winnie Liang, Susan Smalley, and Laura H Goetz. Does modulation of an epigenetic clock define a geroprotector? *Advances in geriatric medicine and research*, 4(1), 2022.

[4] Paul D Yousefi, Matthew Suderman, Ryan Langdon, Oliver Whitehurst, George Davey Smith, and Caroline L Relton. Dna methylation-based predictors of health: applications and statistical considerations. *Nature Reviews Genetics*, 23(6):369–383, 2022.

[5] Juulia Jylhävä, Nancy L Pedersen, and Sara Hägg. Biological age predictors. *EBioMedicine*, 21:29–36, 2017.

[6] Marije H Sluiskes, Jelle J Goeman, Marian Beekman, P Eline Slagboom, Hein Putter, and Mar Rodríguez-Girondo. Clarifying the biological and statistical assumptions of cross-sectional biological age predictors: an elaborate illustration using synthetic and real data. *BMC Medical Research Methodology*, 24(1):58, 2024.

[7] Petr Klemera and Stanislav Doubal. A new approach to the concept and computation of biological age. *Mechanisms of ageing and development*, 127(3):240–248, 2006.

[8] Steve Horvath. Dna methylation age of human tissues and cell types. *Genome biology*, 14:1–20, 2013.

[9] Emma Pierson, Pang Wei Koh, Tatsunori Hashimoto, Daphne Koller, Jure Leskovec, Nick Eriksson, and Percy Liang. Inferring multidimensional rates of aging from cross-sectional data. In *The 22nd International Conference on Artificial Intelligence and Statistics*, pages 97–107. PMLR, 2019.

[10] Jarod Rutledge, Hamilton Oh, and Tony Wyss-Coray. Measuring biological age using omics data. *Nature Reviews Genetics*, 23(12):715–727, 2022.

[11] Anatoly Urban, Denis Sidorenko, Diana Zagirova, Ekaterina Kozlova, Aleksandr Kalashnikov, Stefan Pushkov, Vladimir Naumov, Viktoria Sarkisova, Geoffrey Ho Duen Leung, Hoi Wing Leung, et al. Precious1gpt: multimodal transformer-based transfer learning for aging clock development and feature importance analysis for aging and age-related disease target discovery. *Aging (Albany NY)*, 15(11):4649, 2023.

[12] Evgeny Putin, Polina Mamoshina, Alexander Aliper, Mikhail Korzinkin, Alexey Moskalev, Alexey Kolosov, Alexander Ostrovskiy, Charles Cantor, Jan Vijg, and Alex Zhavoronkov. Deep biomarkers of human aging: application of deep neural networks to biomarker development. *Aging (Albany NY)*, 8(5):1021, 2016.

[13] Xian Xia, Xingwei Chen, Gang Wu, Fang Li, Yiyang Wang, Yang Chen, Mingxu Chen, Xinyu Wang, Weiyang Chen, Bo Xian, et al. Three-dimensional facial-image analysis to predict heterogeneity of the human ageing rate and the impact of lifestyle. *Nature metabolism*, 2(9):946–957, 2020.

[14] Nicholas Holzscheck, Cassandra Falckenhayn, Jörn Söhle, Boris Kristof, Ralf Siegner, André Werner, Janka Schössow, Clemens Jürgens, Henry Völzke, Horst Wenck, et al. Modeling transcriptomic age using knowledge-primed artificial neural networks. *npj Aging and Mechanisms of Disease*, 7(1):15, 2021.

[15] Gregory Hannum, Justin Guinney, Ling Zhao, LI Zhang, Guy Hughes, SriniVas Sadda, Brandy Klotzle, Marina Bibikova, Jian-Bing Fan, Yuan Gao, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Molecular cell*, 49(2):359–367, 2013.

[16] Morgan E Levine, Ake T Lu, Austin Quach, Brian H Chen, Themistocles L Assimes, Stefania Bandinelli, Lifang Hou, Andrea A Baccarelli, James D Stewart, Yun Li, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (albany NY)*, 10(4):573, 2018.

[17] Ake T Lu, Austin Quach, James G Wilson, Alex P Reiner, Abraham Aviv, Kenneth Raj, Lifang Hou, Andrea A Baccarelli, Yun Li, James D Stewart, et al. Dna methylation grimage strongly predicts lifespan and healthspan. *Aging (albany NY)*, 11(2):303, 2019.

[18] Fedor Galkin, Polina Mamoshina, Kirill Kochetov, Denis Sidorenko, and Alex Zhavoronkov. Deepmage: a methylation aging clock developed with deep learning. *Aging and disease*, 12(5):1252, 2021.

[19] Kejun Ying, Hanna Liu, Andrei E Tarkhov, Marie C Sadler, Ake T Lu, Mahdi Moqri, Steve Horvath, Zoltán Kutalik, Xia Shen, and Vadim N Gladyshev. Causality-enriched epigenetic age uncouples damage and adaptation. *Nature Aging*, pages 1–16, 2024.

[20] Alexey Moskalev. *Biomarkers of human aging*, volume 10. Springer, 2019.

[21] Xian Xia, Yiyang Wang, Zhengqing Yu, Jiawei Chen, and Jing-Dong J Han. Assessing the rate of aging to monitor aging itself. *Ageing Research Reviews*, 69:101350, 2021.

[22] Maxim VC Greenberg and Deborah Bourc'his. The diverse roles of dna methylation in mammalian development and disease. *Nature reviews Molecular cell biology*, 20(10):590–607, 2019.

[23] Kirsten Seale, Steve Horvath, Andrew Teschendorff, Nir Eynon, and Sarah Voisin. Making sense of the ageing methylome. *Nature Reviews Genetics*, 23(10):585–605, 2022.

[24] Maria Pia Campagna, Alexandre Xavier, Jeannette Lechner-Scott, Vicky Maltby, Rodney J Scott, Helmut Butzkueven, Vilija G Jokubaitis, and Rodney A Lea. Epigenome-wide association studies: current knowledge, strategies and recommendations. *Clinical epigenetics*, 13:1–24, 2021.

[25] James William Hollingsworth, Asaji Hashizume, and Seymour Jablon. Correlations between tests of aging in hiroshima subjects–an attempt to define" physiologic age". *The Yale journal of biology and medicine*, 38(1):11, 1965.

[26] V P Voitenko and A V Tokar. The assessment of biological age and sex differences of human aging. *Experimental Aging Research*, 9(4):239–244, 12 1983. doi: 10.1080/03610738308258458.

[27] Ravindranath Duggirala, Meredith Uttley, Ken Williams, Rector Arya, John Blangero, and Michael H Crawford. Genetic determination of biological age in the mennonites of the midwestern united states. *Genetic Epidemiology: The Official Publication of the International Genetic Epidemiology Society*, 23(2): 97–109, 2002.

[28] Miri Varshavsky, Gil Harari, Benjamin Glaser, Yuval Dor, Ruth Shemer, and Tommy Kaplan. Accurate age prediction from blood using a small set of dna methylation sites and a cohort-based machine learning algorithm. *Cell Reports Methods*, 3(9), 2023.

[29] Aurel Prosz, Orsolya Pipek, Judit Börcsök, Gergely Palla, Zoltan Szallasi, Sandor Spisak, and István Csabai. Biologically informed deep learning for explainable epigenetic clocks. *Scientific Reports*, 14(1): 1306, 2024.

[30] Lieke M Kuiper, Harmke A Polinder-Bos, Daniele Bizzarri, Dina Vojinovic, Costanza L Vallerga, Marian Beekman, Martijn ET Dollé, Mohsen Ghanbari, Trudy Voortman, Marcel JT Reinders, et al. Epigenetic and metabolomic biomarkers for biological age: a comparative analysis of mortality and frailty risk. *The Journals of Gerontology: Series A*, 78(10):1753–1762, 2023.

[31] Richard Hochschild. Improving the precision of biological age determinations. part 1: a new approach to calculating biological age. *Experimental gerontology*, 24(4):289–300, 1989.

[32] Qian Zhang, Costanza L Vallerga, Rosie M Walker, Tian Lin, Anjali K Henders, Grant W Montgomery, Ji He, Dongsheng Fan, Javed Fowdar, Martin Kennedy, et al. Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. *Genome medicine*, 11:1–11, 2019.

[33] Johannes Hertel, Nele Friedrich, Katharina Wittfeld, Maik Pietzner, Kathrin Budde, Sandra Van der Auwera, Tobias Lohmann, Alexander Teumer, Henry Voolzke, Matthias Nauck, et al. Measuring biological age via metabonomics: the metabolic age score. *Journal of proteome research*, 15(2):400–410, 2016.

[34] Xiaoyue Mei, Joshua Blanchard, Connor Luellen, Michael J Conboy, and Irina M Conboy. Fail-tests of dna methylation clocks, and development of a noise barometer for measuring epigenetic pressure of aging and disease. *Aging (Albany NY)*, 15(17):8552, 2023.

[35] Cuicui Wang, Wenli Ni, Yueli Yao, Allan Just, Jonathan Heiss, Yaguang Wei, Xu Gao, Brent A Coull, Anna Kosheleva, Andrea A Baccarelli, et al. Dna methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: the nas, and kora f4. *EBioMedicine*, 63, 2021.

[36] Tianxiao Huan, Steve Nguyen, Elena Colicino, Carolina Ochoa-Rosales, W David Hill, Jennifer A Brody, Mette Soerensen, Yan Zhang, Antoine Baldassari, Mohamed Ahmed Elhadad, et al. Integrative analysis of clinical and epigenetic biomarkers of mortality. *Aging cell*, 21(6):e13608, 2022.

[37] Olga Chervova, Elizabeth Chernysheva, Kseniia Panteleeva, Tyas Arum Widayati, Natalie Hrbkova, Jadesada Schneider, Vladimir Maximov, Andrew Ryabikov, Taavi Tillmann, Hynek Pikhart, et al. Evaluation of epigenetic age acceleration scores and their associations with cvd-related phenotypes in a population cohort. *Biology*, 12(1):68, 2022.

[38] Zuyun Liu, Diana Leung, Kyra Thrush, Wei Zhao, Scott Ratliff, Toshiko Tanaka, Lauren L Schmitz, Jennifer A Smith, Luigi Ferrucci, and Morgan E Levine. Underlying features of epigenetic aging clocks in vivo and in vitro. *Aging cell*, 19(10):e13229, 2020.

[39] Jane Maddock, Juan Castillo-Fernandez, Andrew Wong, Rachel Cooper, Marcus Richards, Ken K Ong, George B Ploubidis, Alissa Goodman, Diana Kuh, Jordana T Bell, et al. Dna methylation age and physical and cognitive aging. *The Journals of Gerontology: Series A*, 75(3):504–511, 2020.

[40] Cathal McCrory, Giovanni Fiorito, Belinda Hernandez, Silvia Polidoro, Aisling M O'Halloran, Ann Hever, Cliona Ni Cheallaigh, Ake T Lu, Steve Horvath, Paolo Vineis, et al. Grimage outperforms other epigenetic clocks in the prediction of age-related clinical phenotypes and all-cause mortality. *The Journals of Gerontology: Series A*, 76(5):741–749, 2021.

[41] Hunter L Porter, Chase A Brown, Xiavan Roopnarinesingh, Cory B Giles, Constantin Georgescu, Willard M Freeman, and Jonathan D Wren. Many chronological aging clocks can be found throughout the epigenome: Implications for quantifying biological aging. *Aging cell*, 20(11):e13492, 2021.

[42] Kejun Ying, Seth Paulson, Alec Eames, Alexander Tyshkovskiy, Siyuan Li, Martin Perez-Guevara, Mehrnoosh Emamifar, Maximiliano Casas Martínez, Dayoon Kwon, Anna Kosheleva, et al. A unified framework for systematic curation and evaluation of aging biomarkers. *bioRxiv*, pages 2023–12, 2023.

[43] Franziska Schnabel, Uwe Kornak, and Bernd Wollnik. Premature aging disorders: A clinical and genetic compendium. *Clinical Genetics*, 99(1):3–28, 2021.

[44] Zhe Li, Zhenkun Zhang, Yikun Ren, Yingying Wang, Jiarui Fang, Han Yue, Shanshan Ma, and Fangxia Guan. Aging and age-related diseases: from mechanisms to therapeutic strategies. *Biogerontology*, 22(2): 165–187, 2021.

[45] Alize J Ferrari, Damian Francesco Santomauro, Amirali Aali, Yohannes Habtegiorgis Abate, Cristiana Abbafati, Hedayat Abbastabar, Samar Abd ElHafeez, Michael Abdelmasseh, Sherief Abd-Elsalam, Arash Abdollahi, et al. Global incidence, prevalence, years lived with disability (ylds), disability-adjusted life-years (dalys), and healthy life expectancy (hale) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the global burden of disease study 2021. *The Lancet*, 403(10440):2133–2161, 2024.

[46] Steve Horvath, Junko Oshima, George M Martin, Ake T Lu, Austin Quach, Howard Cohen, Sarah Felton, Mieko Matsuyama, Donna Lowe, Sylwia Kabacik, et al. Epigenetic clock for skin and blood cells applied to hutchinson gilford progeria syndrome and ex vivo studies. *Aging (Albany NY)*, 10(7):1758, 2018.

[47] Lindsay M Reynolds, Jackson R Taylor, Jingzhong Ding, Kurt Lohman, Craig Johnson, David Siscovick, Gregory Burke, Wendy Post, Steven Shea, David R Jacobs, Jr, Hendrik Stunnenberg, Stephen B Kritchevsky, Ina Hoeschele, Charles E McCall, David Herrington, Russell P Tracy, and Yongmei Liu. Age-related variations in the methylome associated with gene expression in human monocytes and T cells. *Nat. Commun.*, 5(1):5366, November 2014.

[48] Maria S Nazarenko, Anton V Markov, Igor N Lebedev, Maxim B Freidin, Aleksei A Sleptcov, Iuliya A Koroleva, Aleksei V Frolov, Vadim A Popov, Olga L Barbarash, and Valery P Puzyrev. A comparison of genome-wide DNA methylation patterns between different vascular tissues from patients with coronary heart disease. *PLoS One*, 10(4):e0122601, April 2015.

13

[49] Carolina Soriano-Tárraga, Jordi Jiménez-Conde, Eva Giralt-Steinhauer, Marina Mola-Caminal, Rosa M Vivanco-Hidalgo, Angel Ois, Ana Rodríguez-Campello, Elisa Cuadrado-Godia, Sergi Sayols-Baixeras, Roberto Elosua, Jaume Roquer, and GENESTROKE Consortium. Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycemia. *Hum. Mol. Genet.*, 25(3):609–619, February 2016.

[50] Geoffrey Istas, Ken Declerck, Maria Pudenz, Katarzyna Szarc Vel Szic, Veronica Lendinez-Tortajada, Montserrat Leon-Latre, Karen Heyninck, Guy Haegeman, Jose A Casasnovas, Maria Tellez-Plaza, Clarissa Gerhauser, Christian Heiss, Ana Rodriguez-Mateos, and Wim Vanden Berghe. Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease. *Sci. Rep.*, 7(1):5120, July 2017.

[51] Natalia Cullell, Carolina Soriano-Tárraga, Cristina Gallego-Fábrega, Jara Cárcel-Márquez, Elena Muiño, Laia Llucià-Carol, Miquel Lledós, Manel Esteller, Manuel Castro de Moura, Joan Montaner, Anna Rosell, Pilar Delgado, Joan Martí-Fábregas, Jerzy Krupinski, Jaume Roquer, Jordi Jiménez-Conde, and Israel Fernández-Cadenas. Altered methylation pattern in EXOC4 is associated with stroke outcome: an epigenome-wide association study. *Clin. Epigenetics*, 14(1):124, September 2022.

[52] R Alan Harris, Dorottya Nagy-Szakal, Natalia Pedersen, Antone Opekun, Jiri Bronsky, Pia Munkholm, Cathrine Jespersgaard, Paalskytt Andersen, Bela Melegh, George Ferry, Tine Jess, and Richard Kellermayer. Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases. *Inflamm. Bowel Dis.*, 18(12):2334–2341, December 2012.

[53] Steve Horvath and Andrew J Levine. HIV-1 infection accelerates age according to the epigenetic clock. *J. Infect. Dis.*, 212(10):1563–1573, November 2015.

[54] Andrew M Gross, Philipp A Jaeger, Jason F Kreisberg, Katherine Licon, Kristen L Jepsen, Mahdieh Khosroheidari, Brenda M Morsey, Susan Swindells, Hui Shen, Cherie T Ng, Ken Flagg, Daniel Chen, Kang Zhang, Howard S Fox, and Trey Ideker. Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age and epigenetic targeting of HLA. *Mol. Cell*, 62(2):157–168, April 2016.

[55] Xinyu Zhang, Amy C Justice, Ying Hu, Zuoheng Wang, Hongyu Zhao, Guilin Wang, Eric O Johnson, Brinda Emu, Richard E Sutton, John H Krystal, and Ke Xu. Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals. *Epigenetics*, 11(10):750–760, October 2016.

[56] Andrew Y F Li Yim, Nicolette W Duijvis, Jing Zhao, Wouter J de Jonge, Geert R A M D'Haens, Marcel M A M Mannens, Adri N P M Mul, Anje A Te Velde, and Peter Henneman. Peripheral blood methylation profiling of female crohn's disease patients. *Clin. Epigenetics*, 8(1):65, June 2016.

[57] N T Ventham, N A Kennedy, A T Adams, R Kalla, S Heath, K R O'Leary, H Drummond, IBD BIOM consortium, IBD CHARACTER consortium, D C Wilson, I G Gut, E R Nimmo, and J Satsangi. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. *Nat. Commun.*, 7:13507, November 2016.

[58] Xinyu Zhang, Ying Hu, Amy C Justice, Boyang Li, Zuoheng Wang, Hongyu Zhao, John H Krystal, and Ke Xu. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. *Nat. Commun.*, 8(1):2243, December 2017.

[59] Xinyu Zhang, Ying Hu, Bradley E Aouizerat, Gang Peng, Vincent C Marconi, Michael J Corley, Todd Hulgan, Kendall J Bryant, Hongyu Zhao, John H Krystal, Amy C Justice, and Ke Xu. Machine learning selected smoking-associated DNA methylation signatures that predict HIV prognosis and mortality. *Clin. Epigenetics*, 10(1):155, December 2018.

[60] Bruna Oriol-Tordera, Maria Berdasco, Anuska Llano, Beatriz Mothe, Cristina Gálvez, Javier Martinez-Picado, Jorge Carrillo, Julià Blanco, Clara Duran-Castells, Carmela Ganoza, Jorge Sanchez, Bonaventura Clotet, Maria Luz Calle, Alex Sánchez-Pla, Manel Esteller, Christian Brander, and Marta Ruiz-Riol. Methylation regulation of antiviral host factors, interferon stimulated genes (ISGs) and t-cell responses associated with natural HIV control. *PLoS Pathog.*, 16(8):e1008678, August 2020.

[61] Andrew R DiNardo, Kimal Rajapakshe, Tomoki Nishiguchi, Sandra L Grimm, Godwin Mtetwa, Qiniso Dlamini, Jaqueline Kahari, Sanjana Mahapatra, Alexander Kay, Gugu Maphalala, Emily M Mace, George Makedonas, Jeffrey D Cirillo, Mihai G Netea, Reinout van Crevel, Cristian Coarfa, and Anna M Mandalakas. DNA hypermethylation during tuberculosis dampens host immune responsiveness. *J. Clin. Invest.*, 130(6):3113–3123, June 2020.

14

[62] Bruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, Míriam Rosás-Umbert, Elena Gonçalves, Clara Duran-Castells, Francesc Català-Moll, Anuska Llano, Samandhy Cedeño, Maria C. Puertas, Martin Tolstrup, Ole S. Søgaard, Bonaventura Clotet, Javier Martínez-Picado, Tomáš Hanke, Behazine Combadiere, Roger Paredes, Dennis Hartigan-O'Connor, Manel Esteller, Michael Meulbroek, María Luz Calle, Alex Sanchez-Pla, José Moltó, Beatriz Mothe, Christian Brander, and Marta Ruiz-Riol. Epigenetic landscape in the kick-and-kill therapeutic vaccine bcn02 clinical trial is associated with antiretroviral treatment interruption (ati) outcome. *eBioMedicine*, 78:103956, 4 2022. doi: 10.1016/j.ebiom.2022.103956.

[63] Andrés Esteban-Cantos, Javier Rodríguez-Centeno, Juan C Silla, Pilar Barruz, Fátima Sánchez-Cabo, Gabriel Saiz-Medrano, Julián Nevado, Beatriz Mena-Garay, María Jiménez-González, Rosa de Miguel, Jose I Bernardino, Rocío Montejano, Julen Cadiñanos, Cristina Marcelo, Lucía Gutiérrez-García, Patricia Martínez-Martín, Cédrick Wallet, François Raffi, Berta Rodés, José R Arribas, and NEAT001/ANRS143 study group. Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns. *EBioMedicine*, 88(104434):104434, February 2023.

[64] Yun Liu, Martin J Aryee, Leonid Padyukov, M Daniele Fallin, Espen Hesselberg, Arni Runarsson, Lovisa Reinius, Nathalie Acevedo, Margaret Taub, Marcus Ronninger, Klementy Shchetynsky, Annika Scheynius, Juha Kere, Lars Alfredsson, Lars Klareskog, Tomas J Ekström, and Andrew P Feinberg. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. *Nat. Biotechnol.*, 31(2):142–147, February 2013.

[65] Eduardo Fernandez-Rebollo, Monika Eipel, Lothar Seefried, Per Hoffmann, Klaus Strathmann, Franz Jakob, and Wolfgang Wagner. Primary osteoporosis is not reflected by disease-specific DNA methylation or accelerated epigenetic age in blood. *J. Bone Miner. Res.*, 33(2):356–361, February 2018.

[66] Brooke Rhead, Calliope Holingue, Michael Cole, Xiaorong Shao, Hong L Quach, Diana Quach, Khooshbu Shah, Elizabeth Sinclair, John Graf, Thomas Link, Ruby Harrison, Elior Rahmani, Eran Halperin, Wei Wang, Gary S Firestein, Lisa F Barcellos, and Lindsey A Criswell. Rheumatoid arthritis naive T cells share hypermethylation sites with synoviocytes. *Arthritis Rheumatol.*, 69(3):550–559, March 2017.

[67] Alexander D Clark, Nisha Nair, Amy E Anderson, Nishanthi Thalayasingam, Najib Naamane, Andrew J Skelton, Julie Diboll, Anne Barton, Stephen Eyre, John D Isaacs, Arthur G Pratt, and Louise N Reynard. Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. *J. Allergy Clin. Immunol.*, 145(5):1438–1451, May 2020.

[68] Weiyang Tao, Arno N Concepcion, Marieke Vianen, Anne C A Marijnissen, Floris P G J Lafeber, Timothy R D J Radstake, and Aridaman Pandit. Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. *Arthritis Rheumatol.*, 73(2):212–222, February 2021.

[69] Carlos de la Calle-Fabregat, Ellis Niemantsverdriet, Juan D Cañete, Tianlu Li, Annette H M van der Helm-van Mil, Javier Rodríguez-Ubreva, and Esteban Ballestar. Prediction of the progression of undifferentiated arthritis to rheumatoid arthritis using DNA methylation profiling. *Arthritis Rheumatol.*, 73(12):2229–2239, December 2021.

[70] Antonio Julià, Antonio Gómez, María López-Lasanta, Francisco Blanco, Alba Erra, Antonio Fernández-Nebro, Antonio Juan Mas, Carolina Pérez-García, Ma Luz García Vivar, Simón Sánchez-Fernández, Mercedes Alperi-López, Raimon Sanmartí, Ana María Ortiz, Carlos Marras Fernandez-Cid, César Díaz-Torné, Estefania Moreno, Tianlu Li, Sergio H Martínez-Mateu, Devin M Absher, Richard M Myers, Jesús Tornero Molina, and Sara Marsal. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. *EBioMedicine*, 80(104053):104053, June 2022.

[71] Yulan Chen, Qiao Wang, Haina Liu, Lei Jin, Xin Feng, Bingbing Dai, Meng Chen, Fangran Xin, Tingting Wei, Bingqing Bai, Zhijun Fan, Jiahui Li, Yuxin Yao, Ruobing Liao, Jintao Zhang, Xiangnan Jin, and Lingyu Fu. The prognostic value of whole-genome DNA methylation in response to leflunomide in patients with rheumatoid arthritis. *Front. Immunol.*, 14:1173187, September 2023.

[72] Kenneth Day, Lindsay L Waite, Anna Thalacker-Mercer, Andrew West, Marcas M Bamman, James D Brooks, Richard M Myers, and Devin Absher. Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. *Genome Biol.*, 14(9):R102, 2013.

[73] Vardhman K. Rakyan, Huriya Beyan, Thomas A. Down, Mohammed I. Hawa, Siarhei Maslau, Deeqo Aden, Antoine Daunay, Florence Busato, Charles A. Mein, Burkhard Manfras, Kerith-Rae M. Dias, Christopher G. Bell, Jörg Tost, Bernhard O. Boehm, Stephan Beck, and R. David Leslie. Identification of type 1 diabetes–associated dna methylation variable positions that precede disease diagnosis. *PLoS Genetics*, 7(9):e1002300, 9 2011. doi: 10.1371/journal.pgen.1002300.

[74] Katie Lunnon, Rebecca G Smith, Itzik Cooper, Lior Greenbaum, Jonathan Mill, and Michal Schnaider Beeri. Blood methylomic signatures of presymptomatic dementia in elderly subjects with type 2 diabetes mellitus. *Neurobiol. Aging*, 36(3):1600.e1–4, March 2015.

[75] Bruno Ramos-Molina, Lidia Sánchez-Alcoholado, Amanda Cabrera-Mulero, Raul Lopez-Dominguez, Pedro Carmona-Saez, Eduardo Garcia-Fuentes, Isabel Moreno-Indias, and Francisco J Tinahones. Gut microbiota composition is associated with the global DNA methylation pattern in obesity. *Front. Genet.*, 10:613, July 2019.

[76] Natália Yumi Noronha, Mariana Barato, Chanachai Sae-Lee, Marcela Augusta de Souza Pinhel, Lígia Moriguchi Watanabe, Vanessa Aparecida Batista Pereira, Guilherme da Silva Rodrigues, Déborah Araújo Morais, Wellington Tavares de Sousa, Jr, Vanessa Cristina de Oliveira Souza, Jessica Rodrigues Plaça, Wilson Salgado, Jr, Fernando Barbosa, Jr, Torsten Plösch, and Carla Barbosa Nonino. Novel zinc-related differentially methylated regions in leukocytes of women with and without obesity. *Front. Nutr.*, 9:785281, March 2022.

[77] Francesco Marabita, Malin Almgren, Maléne E Lindholm, Sabrina Ruhrmann, Fredrik Fagerström-Billai, Maja Jagodic, Carl J Sundberg, Tomas J Ekström, Andrew E Teschendorff, Jesper Tegnér, and David Gomez-Cabrero. An evaluation of analysis pipelines for DNA methylation profiling using the illumina HumanMethylation450 BeadChip platform. *Epigenetics*, 8(3):333–346, March 2013.

[78] Katie Lunnon, Rebecca Smith, Eilis Hannon, Philip L De Jager, Gyan Srivastava, Manuela Volta, Claire Troakes, Safa Al-Sarraj, Joe Burrage, Ruby Macdonald, Daniel Condliffe, Lorna W Harries, Pavel Katsel, Vahram Haroutunian, Zachary Kaminsky, Catharine Joachim, John Powell, Simon Lovestone, David A Bennett, Leonard C Schalkwyk, and Jonathan Mill. Methylomic profiling implicates cortical deregulation of ANK1 in alzheimer's disease. *Nat. Neurosci.*, 17(9):1164–1170, September 2014.

[79] Steve Horvath and Beate R Ritz. Increased epigenetic age and granulocyte counts in the blood of parkinson's disease patients. *Aging (Albany NY)*, 7(12):1130–1142, December 2015.

[80] Kamilah Castro, Achilles Ntranos, Mario Amatruda, Maria Petracca, Peter Kosa, Emily Y Chen, Johannes Morstein, Dirk Trauner, Corey T Watson, Michael A Kiebish, Bibiana Bielekova, Matilde Inglese, Ilana Katz Sand, and Patrizia Casaccia. Body mass index in multiple sclerosis modulates ceramide-induced DNA methylation and disease course. *EBioMedicine*, 43:392–410, May 2019.

[81] Lara Kular, Yun Liu, Sabrina Ruhrmann, Galina Zheleznyakova, Francesco Marabita, David Gomez-Cabrero, Tojo James, Ewoud Ewing, Magdalena Lindén, Bartosz Górnikiewicz, Shahin Aeinehband, Pernilla Stridh, Jenny Link, Till F M Andlauer, Christiane Gasperi, Heinz Wiendl, Frauke Zipp, Ralf Gold, Björn Tackenberg, Frank Weber, Bernhard Hemmer, Konstantin Strauch, Stefanie Heilmann-Heimbach, Rajesh Rawal, Ulf Schminke, Carsten O Schmidt, Tim Kacprowski, Andre Franke, Matthias Laudes, Alexander T Dilthey, Elisabeth G Celius, Helle B Søndergaard, Jesper Tegnér, Hanne F Harbo, Annette B Oturai, Sigurgeir Olafsson, Hannes P Eggertsson, Bjarni V Halldorsson, Haukur Hjaltason, Elias Olafsson, Ingileif Jonsdottir, Kari Stefansson, Tomas Olsson, Fredrik Piehl, Tomas J Ekström, Ingrid Kockum, Andrew P Feinberg, and Maja Jagodic. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis. *Nat. Commun.*, 9(1):2397, June 2018.

[82] Yu-Hsuan Chuang, Kimberly C Paul, Jeff M Bronstein, Yvette Bordelon, Steve Horvath, and Beate Ritz. Parkinson's disease is associated with DNA methylation levels in human blood and saliva. *Genome Med.*, 9(1):76, August 2017.

[83] Yu-Hsuan Chuang, Ake T Lu, Kimberly C Paul, Aline D Folle, Jeff M Bronstein, Yvette Bordelon, Steve Horvath, and Beate Ritz. Longitudinal epigenome-wide methylation study of cognitive decline and motor progression in parkinson's disease. *J. Parkinsons. Dis.*, 9(2):389–400, 2019.

[84] Achilles Ntranos, Vasilis Ntranos, Valentina Bonnefil, Jia Liu, Seunghee Kim-Schulze, Ye He, Yunjiao Zhu, Rachel Brandstadter, Corey T Watson, Andrew J Sharp, Ilana Katz Sand, and Patrizia Casaccia. Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis. *Brain*, 142(3):647–661, March 2019.

[85] Ewoud Ewing, Lara Kular, Sunjay J Fernandes, Nestoras Karathanasis, Vincenzo Lagani, Sabrina Ruhrmann, Ioannis Tsamardinos, Jesper Tegner, Fredrik Piehl, David Gomez-Cabrero, and Maja Jagodic. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during multiple sclerosis progression. *EBioMedicine*, 43:411–423, May 2019.

16

[86] Karl E Carlström, Ewoud Ewing, Mathias Granqvist, Alexandra Gyllenberg, Shahin Aeinehband, Sara Lind Enoksson, Antonio Checa, Tejaswi V S Badam, Jesse Huang, David Gomez-Cabrero, Mika Gustafsson, Faiez Al Nimer, Craig E Wheelock, Ingrid Kockum, Tomas Olsson, Maja Jagodic, and Fredrik Piehl. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. *Nat. Commun.*, 10(1):3081, July 2019.

[87] Janou A Y Roubroeks, Adam R Smith, Rebecca G Smith, Ehsan Pishva, Zina Ibrahim, Martina Sattlecker, Eilis J Hannon, Iwona Kłoszewska, Patrizia Mecocci, Hilkka Soininen, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Dag Aarsland, Petroula Proitsi, Angela Hodges, Simon Lovestone, Stephen J Newhouse, Richard J B Dobson, Jonathan Mill, Daniël L A van den Hove, and Katie Lunnon. An epigenome-wide association study of alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. *Neurobiol. Aging*, 95:26–45, November 2020.

[88] Rodney C P Go, Michael J Corley, G Webster Ross, Helen Petrovitch, Kamal H Masaki, Alika K Maunakea, Qimei He, and Maarit I Tiirikainen. Genome-wide epigenetic analyses in japanese immigrant plantation workers with parkinson's disease and exposure to organochlorines reveal possible involvement of glial genes and pathways involved in neurotoxicity. *BMC Neurosci.*, 21(1):31, July 2020.

[89] Luke C Dabin, Fernando Guntoro, Tracy Campbell, Tony Bélicard, Adam R Smith, Rebecca G Smith, Rachel Raybould, Jonathan M Schott, Katie Lunnon, Peter Sarkies, John Collinge, Simon Mead, and Emmanuelle Viré. Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. *Acta Neuropathol.*, 140(6):863–879, December 2020.

[90] Jeremy M Bingen, Lindsay V Clark, Mark R Band, Ilyas Munzir, and Michael D Carrithers. Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. *Front. Genet.*, 13:1058817, 2022.

[91] Maria M Esterhuyse, January Weiner, 3rd, Etienne Caron, Andre G Loxton, Marco Iannaccone, Chandre Wagman, Philippe Saikali, Kim Stanley, Witold E Wolski, Hans-Joachim Mollenkopf, Matthias Schick, Ruedi Aebersold, Heinz Linhart, Gerhard Walzl, and Stefan H E Kaufmann. Epigenetics and proteomics join transcriptomics in the quest for tuberculosis biomarkers. *MBio*, 6(5):e01187–15, September 2015.

[92] Yung-Che Chen, Ying-Huang Tsai, Chin-Chou Wang, Shih-Feng Liu, Ting-Wen Chen, Wen-Feng Fang, Chiu-Ping Lee, Po-Yuan Hsu, Tung-Ying Chao, Chao-Chien Wu, Yu-Feng Wei, Huang-Chih Chang, Chia-Cheng Tsen, Yu-Ping Chang, Meng-Chih Lin, and Taiwan Clinical Trial Consortium of Respiratory Disease (TCORE) group. Epigenome-wide association study on asthma and chronic obstructive pulmonary disease overlap reveals aberrant DNA methylations related to clinical phenotypes. *Sci. Rep.*, 11(1):5022, March 2021.

[93] Yung-Che Chen, Chang-Chun Hsiao, Ting-Wen Chen, Chao-Chien Wu, Tung-Ying Chao, Sum-Yee Leung, Hock-Liew Eng, Chiu-Ping Lee, Ting-Ya Wang, and Meng-Chih Lin. Whole genome DNA methylation analysis of active pulmonary tuberculosis disease identifies novel epigenotypes: PARP9/miR-505/RASGRP4/GNG12 gene methylation and clinical phenotypes. *Int. J. Mol. Sci.*, 21(9):3180, April 2020.

[94] Anna Maierhofer, Julia Flunkert, Junko Oshima, George M Martin, Martin Poot, Indrajit Nanda, Marcus Dittrich, Tobias Müller, and Thomas Haaf. Epigenetic signatures of werner syndrome occur early in life and are distinct from normal epigenetic aging processes. *Aging Cell*, 18(5):e12995, October 2019.

[95] Yosra Bejaoui, Aleem Razzaq, Noha A Yousri, Junko Oshima, Andre Megarbane, Abeer Qannan, Ramya Potabattula, Tanvir Alam, George M Martin, Henning F Horn, Thomas Haaf, Steve Horvath, and Nady El Hajj. DNA methylation signatures in blood DNA of Hutchinson-Gilford progeria syndrome. *Aging Cell*, 21(2):e13555, February 2022.

[96] Abeer Qannan, Yosra Bejaoui, Mahmoud Izadi, Noha A Yousri, Aleem Razzaq, Colette Christiansen, George M Martin, Jordana T Bell, Steve Horvath, Junko Oshima, Andre Megarbane, Johan Ericsson, Ehsan Pourkarimi, and Nady El Hajj. Accelerated epigenetic aging and DNA methylation alterations in Berardinelli-Seip congenital lipodystrophy. *Hum. Mol. Genet.*, 32(11):1826–1835, May 2023.

[97] Qiong Lin, Carola I Weidner, Ivan G Costa, Riccardo E Marioni, Marcelo RP Ferreira, Ian J Deary, and Wolfgang Wagner. Dna methylation levels at individual age-associated cpg sites can be indicative for life expectancy. *Aging (Albany NY)*, 8(2):394, 2016.

[98] Laura Vidal-Bralo, Yolanda Lopez-Golan, and Antonio Gonzalez. Simplified assay for epigenetic age estimation in whole blood of adults. *Frontiers in genetics*, 7:126, 2016.

17

[99] Albert T Higgins-Chen, Kyra L Thrush, Yunzhang Wang, Christopher J Minteer, Pei-Lun Kuo, Meng Wang, Peter Niimi, Gabriel Sturm, Jue Lin, Ann Zenobia Moore, et al. A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. *Nature aging*, 2(7):644–661, 2022.

[100] Ake T Lu, Alexandra M Binder, Joshua Zhang, Qi Yan, Alex P Reiner, Simon R Cox, Janie Corley, Sarah E Harris, Pei-Lun Kuo, Ann Z Moore, et al. Dna methylation grimage version 2. *Aging (Albany NY)*, 14(23):9484, 2022.

[101] Abner T Apsley, Qiaofeng Ye, Avshalom Caspi, Christopher Chiaro, Laura Etzel, Waylon J Hastings, Christine M Heim, John Kozlosky, Jennie G Noll, Hannah MC Schreier, Chad E Shenk, Karen Sugden, and Idan Shalev. Cross-tissue comparison of epigenetic aging clocks in humans. *Aging Cell*, 1 2025. doi: 10.1111/acel.14451.

[102] Alena Kalyakulina, Igor Yusipov, Elena Kondakova, Maria Giulia Bacalini, Cristina Giuliani, Tatiana Sivtseva, Sergey Semenov, Artem Ksenofontov, Maria Nikolaeva, Elza Khusnutdinova, et al. Epigenetics of the far northern yakutian population. *Clinical Epigenetics*, 15(1):189, 2023.

[103] Wanding Zhou, Timothy J Triche Jr, Peter W Laird, and Hui Shen. Sesame: reducing artifactual detection of dna methylation by infinium beadchips in genomic deletions. *Nucleic acids research*, 46(20):e123–e123, 2018.

[104] Ersilia Paparazzo, Vincenzo Lagani, Silvana Geracitano, Luigi Citrigno, Mirella Aurora Aceto, Antonio Malvaso, Francesco Bruno, Giuseppe Passarino, and Alberto Montesanto. An elovl2-based epigenetic clock for forensic age prediction: a systematic review. *International Journal of Molecular Sciences*, 24 (3):2254, 2023.

[105] Loukia G Tsaprouni, Tsun-Po Yang, Jordana Bell, Katherine J Dick, Stavroula Kanoni, James Nisbet, Ana Viñuela, Elin Grundberg, Christopher P Nelson, Eshwar Meduri, Alfonso Buil, Francois Cambien, Christian Hengstenberg, Jeanette Erdmann, Heribert Schunkert, Alison H Goodall, Willem H Ouwehand, Emmanouil Dermitzakis, Tim D Spector, Nilesh J Samani, and Panos Deloukas. Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. *Epigenetics*, 9(10):1382–1396, October 2014.

[106] Christiana A Demetriou, Jia Chen, Silvia Polidoro, Karin van Veldhoven, Cyrille Cuenin, Gianluca Campanella, Kevin Brennan, Françoise Clavel-Chapelon, Laure Dossus, Marina Kvaskoff, Dagmar Drogan, Heiner Boeing, Rudolf Kaaks, Angela Risch, Dimitrios Trichopoulos, Pagona Lagiou, Giovanna Masala, Sabina Sieri, Rosario Tumino, Salvatore Panico, J Ramón Quirós, María-José Sánchez Perez, Pilar Amiano, José María Huerta Castaño, Eva Ardanaz, Charlotte Onland-Moret, Petra Peeters, Kay-Tee Khaw, Nick Wareham, Timothy J Key, Ruth C Travis, Isabelle Romieu, Valentina Gallo, Marc Gunter, Zdenko Herceg, Kyriacos Kyriacou, Elio Riboli, James M Flanagan, and Paolo Vineis. Methylome analysis and epigenetic changes associated with menarcheal age. *PLoS One*, 8(11):e79391, November 2013.

[107] Na Zhang, Shumin Zhao, Su-Hua Zhang, Jinzhong Chen, Daru Lu, Min Shen, and Chengtao Li. Intramonozygotic twin pair discordance and longitudinal variation of whole-genome scale DNA methylation in adults. *PLoS One*, 10(8):e0135022, August 2015.

[108] J T Bell, A K Loomis, L M Butcher, F Gao, B Zhang, C L Hyde, J Sun, H Wu, K Ward, J Harris, S Scollen, M N Davies, L C Schalkwyk, J Mill, MuTHER Consortium, F M K Williams, N Li, P Deloukas, S Beck, S B McMahon, J Wang, S L John, and T D Spector. Differential methylation of the TRPA1 promoter in pain sensitivity. *Nature Communications*, 5:2978, 2014.

[109] Yun Li, Jason A Chen, Renee L Sears, Fuying Gao, Eric D Klein, Anna Karydas, Michael D Geschwind, Howard J Rosen, Adam L Boxer, Weilong Guo, Matteo Pellegrini, Steve Horvath, Bruce L Miller, Daniel H Geschwind, and Giovanni Coppola. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. *PLoS Genetics*, 10(3): e1004211, March 2014.

[110] Allan F McRae, Joseph E Powell, Anjali K Henders, Lisa Bowdler, Gibran Hemani, Sonia Shah, Jodie N Painter, Nicholas G Martin, Peter M Visscher, and Grant W Montgomery. Contribution of genetic variation to transgenerational inheritance of DNA methylation. *Genome Biology*, 15(5):R73, May 2014.

[111] Liina Tserel, Raivo Kolde, Maia Limbach, Konstantin Tretyakov, Silva Kasela, Kai Kisand, Mario Saare, Jaak Vilo, Andres Metspalu, Lili Milani, and Pärt Peterson. Age-related profiling of DNA methylation in CD8+ T cells reveals changes in immune response and transcriptional regulator genes. *Scientific Reports*, 5(1):13107, August 2015.

[112] James M Flanagan, Mark N Brook, Nick Orr, Katarzyna Tomczyk, Penny Coulson, Olivia Fletcher, Michael E Jones, Minouk J Schoemaker, Alan Ashworth, Anthony Swerdlow, Robert Brown, and Montserrat Garcia-Closas. Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study. *Cancer Epidemiology, Biomarkers & Prevention*, 24(1):221–229, January 2015.

[113] Weiwei Zhang, Tim D Spector, Panos Deloukas, Jordana T Bell, and Barbara E Engelhardt. Predicting genome-wide dna methylation using methylation marks, genomic position, and dna regulatory elements. *Genome biology*, 16:1–20, 2015.

[114] Cheng Xu, Hongzhu Qu, Guangyu Wang, Bingbing Xie, Yi Shi, Yaran Yang, Zhao Zhao, Lan Hu, Xiangdong Fang, Jiangwei Yan, and Lei Feng. A novel strategy for forensic age prediction by DNA methylation and support vector regression model. *Scientific Reports*, 5(1):17788, December 2015.

[115] Rubina Tabassum, Ambily Sivadas, Vartika Agrawal, Haozheng Tian, Dalia Arafat, and Greg Gibson. Omic personality: implications of stable transcript and methylation profiles for personalized medicine. *Genome Medicine*, 7(1):88, August 2015.

[116] Steve Horvath, Michael Gurven, Morgan E Levine, Benjamin C Trumble, Hillard Kaplan, Hooman Allayee, Beate R Ritz, Brian Chen, Ake T Lu, Tammy M Rickabaugh, Beth D Jamieson, Dianjianyi Sun, Shengxu Li, Wei Chen, Lluis Quintana-Murci, Maud Fagny, Michael S Kobor, Philip S Tsao, Alexander P Reiner, Kerstin L Edlefsen, Devin Absher, and Themistocles L Assimes. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome Biology*, 17(1):171, August 2016.

[117] Dieuwertje E G Kok, Rosalie A M Dhonukshe-Rutten, Carolien Lute, Sandra G Heil, André G Uitterlinden, Nathalie van der Velde, Joyce B J van Meurs, Natasja M van Schoor, Guido J E J Hooiveld, Lisette C P G M de Groot, Ellen Kampman, and Wilma T Steegenga. The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects. *Clinical Epigenetics*, 7(1):121, November 2015.

[118] Lotte C Houtepen, Christiaan H Vinkers, Tania Carrillo-Roa, Marieke Hiemstra, Pol A van Lier, Wim Meeus, Susan Branje, Christine M Heim, Charles B Nemeroff, Jonathan Mill, Leonard C Schalkwyk, Menno P Creyghton, René S Kahn, Marian Joëls, Elisabeth B Binder, and Marco P M Boks. Genome-wide DNA methylation levels and altered cortisol stress reactivity following childhood trauma in humans. *Nature Communications*, 7(1):10967, March 2016.

[119] Elmar W Tobi, Roderick C Slieker, René Luijk, Koen F Dekkers, Aryeh D Stein, Kate M Xu, Biobank-based Integrative Omics Studies Consortium, P Eline Slagboom, Erik W van Zwet, L H Lumey, and Bastiaan T Heijmans. DNA methylation as a mediator of the association between prenatal adversity and risk factors for metabolic disease in adulthood. *Science Advances*, 4(1):eaao4364, January 2018.

[120] Eilis Hannon, Emma Dempster, Joana Viana, Joe Burrage, Adam R Smith, Ruby Macdonald, David St Clair, Colette Mustard, Gerome Breen, Sebastian Therman, Jaakko Kaprio, Timothea Toulopoulou, Hilleke E Hulshoff Pol, Marc M Bohlken, Rene S Kahn, Igor Nenadic, Christina M Hultman, Robin M Murray, David A Collier, Nick Bass, Hugh Gurling, Andrew McQuillin, Leonard Schalkwyk, and Jonathan Mill. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. *Genome Biology*, 17(1):176, August 2016.

[121] Leonie Roos, Jenny van Dongen, Christopher G Bell, Andrea Burri, Panos Deloukas, Dorret I Boomsma, Tim D Spector, and Jordana T Bell. Integrative dna methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. *Clinical epigenetics*, 8:7, 1 2016. ISSN 1868-7075. doi: 10.1186/s13148-016-0172-y.

[122] R D Edgar, M J Jones, M J Meaney, G Turecki, and M S Kobor. Becon: a tool for interpreting dna methylation findings from blood in the context of brain. *Translational psychiatry*, 7(8):e1187, 8 2017. ISSN 2158-3188. doi: 10.1038/tp.2017.171.

[123] Stancy Joseph, Nysia I George, Bridgett Green-Knox, Edward L Treadwell, Beverly Word, Sarah Yim, and Beverly Lyn-Cook. Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: Identifying dna methylation signatures associated with interferon-related genes based on ethnicity and sledai. *Journal of autoimmunity*, 96:147–157, 1 2019. ISSN 0896-8411. doi: 10.1016/j.jaut.2018.09.007.

[124] Lucas A Salas, Devin C Koestler, Rondi A Butler, Helen M Hansen, John K Wiencke, Karl T Kelsey, and Brock C Christensen. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the illumina humanmethylationepic beadarray. *Genome biology*, 19(1):64, 5 2018. ISSN 1474-7596. doi: 10.1186/s13059-018-1448-7.

[125] Jan Maarten Cobben, Izabela M Krzyzewska, Andrea Venema, Adri N Mul, Abeltje Polstra, Alex V Postma, Robert Smigiel, Karolina Pesz, Jacek Niklinski, Monika A Chomczyk, Peter Henneman, and Marcel Mam Mannens. DNA methylation abundantly associates with fetal alcohol spectrum disorder and its subphenotypes. *Epigenomics*, 11(7):767–785, May 2019.

[126] Bethany Crawford, Zoe Craig, Georgina Mansell, Isobel White, Adam Smith, Steve Spaull, Jennifer Imm, Eilis Hannon, Andrew Wood, Hanieh Yaghootkar, et al. Dna methylation and inflammation marker profiles associated with a history of depression. *Human molecular genetics*, 27(16):2840–2850, 2018.

[127] M P Boks, L C Houtepen, Z Xu, Y He, G Ursini, A X Maihofer, P Rajarajan, Q Yu, H Xu, Y Wu, S Wang, J P Shi, H E Hulshoff Pol, E Strengman, B P F Rutten, A E Jaffe, J E Kleinman, D G Baker, E M Hol, S Akbarian, C M Nievergelt, L D De Witte, C H Vinkers, D R Weinberger, J Yu, and R S. Kahn. Genetic vulnerability to dusp22 promoter hypermethylation is involved in the relation between in utero famine exposure and schizophrenia. *npj Schizophrenia*, 4(1), 8 2018. doi: 10.1038/s41537-018-0058-4.

[128] Aldo Córdova-Palomera, Helena Palma-Gudiel, Jaume Forés-Martos, Rafael Tabarés-Seisdedos, and Lourdes Fañanás. Epigenetic outlier profiles in depression: A genome-wide DNA methylation analysis of monozygotic twins. *PLoS One*, 13(11):e0207754, November 2018.

[129] Ina Zaimi, Dong Pei, Devin C Koestler, Carmen J Marsit, Immaculata De Vivo, Shelley S Tworoger, Alexandra E Shields, Karl T Kelsey, and Dominique S Michaud. Variation in DNA methylation of human blood over a 1-year period using the illumina MethylationEPIC array. *Epigenetics*, 13(10-11):1056–1071, October 2018.

[130] Janine Arloth, Gökcen Eraslan, Till F M Andlauer, Jade Martins, Stella Iurato, Brigitte Kühnel, Melanie Waldenberger, Josef Frank, Ralf Gold, Bernhard Hemmer, Felix Luessi, Sandra Nischwitz, Friedemann Paul, Heinz Wiendl, Christian Gieger, Stefanie Heilmann-Heimbach, Tim Kacprowski, Matthias Laudes, Thomas Meitinger, Annette Peters, Rajesh Rawal, Konstantin Strauch, Susanne Lucae, Bertram Müller-Myhsok, Marcella Rietschel, Fabian J Theis, Elisabeth B Binder, and Nikola S Mueller. DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. *PLoS Computational Biology*, 16(2):e1007616, February 2020.

[131] Anthony S Zannas, Meiwen Jia, Kathrin Hafner, Jens Baumert, Tobias Wiechmann, Julius C Pape, Janine Arloth, Maik Ködel, Silvia Martinelli, Maria Roitman, et al. Epigenetic upregulation of fkbp5 by aging and stress contributes to nf-κb–driven inflammation and cardiovascular risk. *Proceedings of the National Academy of Sciences*, 116(23):11370–11379, 2019.

[132] Alexandra H Bartlett, Jane W Liang, Jose Vladimir Sandoval-Sierra, Jay H Fowke, Eleanor M Simonsick, Karen C Johnson, and Khyobeni Mozhui. Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults. *Biomarker Research*, 7(1):10, May 2019.

[133] Randi K Johnson, Lauren A Vanderlinden, Fran Dong, Patrick M Carry, Jennifer Seifert, Kathleen Waugh, Hanan Shorrosh, Tasha Fingerlin, Brigitte I Frohnert, Ivana V Yang, Katerina Kechris, Marian Rewers, and Jill M Norris. Longitudinal DNA methylation differences precede type 1 diabetes. *Scientific Reports*, 10(1):3721, February 2020.

[134] Kenneth Westerman, Jennifer M Kelly, José M Ordovás, Sarah L Booth, and Dawn L DeMeo. Epigenome-wide association study reveals a molecular signature of response to phylloquinone (vitamin k1) supplementation. *Epigenetics*, 15(8):859–870, August 2020.

[135] Chirag M Vyas, Aditi Hazra, Shun-Chiao Chang, Weiliang Qiu, Charles F Reynolds 3rd, David Mischoulon, Grace Chang, JoAnn E Manson, Immaculata De Vivo, and Olivia I Okereke. Pilot study of dna methylation, molecular aging markers and measures of health and well-being in aging. *Translational psychiatry*, 9(1):118, mar 2019.

[136] Oliver Robinson, Marc Chadeau Hyam, Ibrahim Karaman, Rui Climaco Pinto, Mika Ala-Korpela, Evangelos Handakas, Giovanni Fiorito, He Gao, Andy Heard, Marjo-Riitta Jarvelin, Matthew Lewis, Raha Pazoki, Silvia Polidoro, Ioanna Tzoulaki, Matthias Wielscher, Paul Elliott, and Paolo Vineis. Determinants of accelerated metabolomic and epigenetic aging in a UK cohort. *Aging Cell*, 19(6):e13149, June 2020.

[137] Eilis Hannon, Emma L Dempster, Georgina Mansell, Joe Burrage, Nick Bass, Marc M Bohlken, Aiden Corvin, Charles J Curtis, David Dempster, Marta Di Forti, Timothy G Dinan, Gary Donohoe, Fiona Gaughran, Michael Gill, Amy Gillespie, Cerisse Gunasinghe, Hilleke E Hulshoff, Christina M Hultman, Viktoria Johansson, René S Kahn, Jaakko Kaprio, Gunter Kenis, Kaarina Kowalec, James MacCabe, Colm McDonald, Andrew McQuillin, Derek W Morris, Kieran C Murphy, Colette J Mustard, Igor Nenadic, Michael C O'Donovan, Diego Quattrone, Alexander L Richards, Bart Pf Rutten, David St Clair,

Sebastian Therman, Timothea Toulopoulou, Jim Van Os, John L Waddington, Wellcome Trust Case Control Consortium (WTCCC), CRESTAR consortium, Patrick Sullivan, Evangelos Vassos, Gerome Breen, David Andrew Collier, Robin M Murray, Leonard S Schalkwyk, and Jonathan Mill. DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. *eLife*, 10, February 2021.

[138] Iain R Konigsberg, Bret Barnes, Monica Campbell, Elizabeth Davidson, Yingfei Zhen, Olivia Pallisard, Meher Preethi Boorgula, Corey Cox, Debmalya Nandy, Souvik Seal, et al. Host methylation predicts sars-cov-2 infection and clinical outcome. *Communications medicine*, 1(1):42, 2021.

[139] Zongli Xu, Liang Niu, and Jack A Taylor. The ENmix DNA methylation analysis pipeline for illumina BeadChip and comparisons with seven other preprocessing pipelines. *Clinical epigenetics*, 13(1):216, December 2021.

[140] Joseph Balnis, Andy Madrid, Kirk J Hogan, Lisa A Drake, Hau C Chieng, Anupama Tiwari, Catherine E Vincent, Amit Chopra, Peter A Vincent, Michael D Robek, Harold A Singer, Reid S Alisch, and Ariel Jaitovich. Blood DNA methylation and COVID-19 outcomes. *Clinical epigenetics*, 13(1):118, May 2021.

[141] Guillermo Barturen, Elena Carnero-Montoro, Manuel Martínez-Bueno, Silvia Rojo-Rello, Beatriz Sobrino, Óscar Porras-Perales, Clara Alcántara-Domínguez, David Bernardo, and Marta E Alarcón-Riquelme. Whole blood dna methylation analysis reveals respiratory environmental traits involved in covid-19 severity following sars-cov-2 infection. *Nature Communications*, 13(1):4597, 2022.

[142] Roshni Roy, Senthilkumar Ramamoorthy, Benjamin D Shapiro, Mary Kaileh, Dena Hernandez, Dimitra Sarantopoulou, Sampath Arepalli, Sören Boller, Amit Singh, Arsun Bektas, Jaekwan Kim, Ann Zenobia Moore, Toshiko Tanaka, Julia McKelvey, Linda Zukley, Cuong Nguyen, Tonya Wallace, Christopher Dunn, Robert Wersto, William Wood, Yulan Piao, Kevin G Becker, Christopher Coletta, Supriyo De, Jyoti Misra Sen, Alexis Battle, Nan-Ping Weng, Rudolf Grosschedl, Luigi Ferrucci, and Ranjan Sen. DNA methylation signatures reveal that distinct combinations of transcription factors specify human immune cell epigenetic identity. *Immunity*, 54(11):2465–2480.e5, November 2021.

[143] Amy P Webster, Simone Ecker, Ismail Moghul, Xiaohong Liu, Pawan Dhami, Sarah Marzi, Dirk S Paul, Michelle Kuxhausen, Stephanie J Lee, Stephen R Spellman, et al. Donor whole blood dna methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation. *Frontiers in Genetics*, 15:1242636, 2024.

[144] Jianbo Xiu, Jiayu Li, Zeyue Liu, Hui Wei, Caiyun Zhu, Rongrong Han, Zijing Liu, Wanwan Zhu, Yan Shen, and Qi Xu. Elevated bicd2 dna methylation in blood of major depressive disorder patients and reduction of depressive-like behaviors in hippocampal bicd2-knockdown mice. *Proceedings of the National Academy of Sciences*, 119(30):e2201967119, 2022.

[145] James Clement, Qi Yan, Megha Agrawal, Ramon E Coronado, John A Sturges, Markus Horvath, Ake T Lu, Robert T Brooke, and Steve Horvath. Umbilical cord plasma concentrate has beneficial effects on dna methylation grimage and human clinical biomarkers. *Aging Cell*, 21(10):e13696, 2022.

[146] Brady M Owen, James Phie, Jennifer Huynh, Scott Needham, and Cameron Fraser. Evaluation of quantitative biomarkers of aging in human pbmcs. *Frontiers in Aging*, 4:1260502, 2023.

[147] Dmitrii Kriukov, Ekaterina Kuzmina, Evgeniy Efimov, Dmitry V Dylov, and Ekaterina E Khrameeva. Epistemic uncertainty challenges aging clock reliability in predicting rejuvenation effects. *Aging Cell*, 23(11):e14283, 2024.

[148] Nicholas Schaum, Benoit Lehallier, Oliver Hahn, Róbert Pálovics, Shayan Hosseinzadeh, Song E Lee, Rene Sit, Davis P Lee, Patricia Morán Losada, Macy E Zardeneta, et al. Ageing hallmarks exhibit organ-specific temporal signatures. *Nature*, 583(7817):596–602, 2020.

[149] Hamilton Se-Hwee Oh, Jarod Rutledge, Daniel Nachun, Róbert Pálovics, Olamide Abiose, Patricia Moran-Losada, Divya Channappa, Deniz Yagmur Urey, Kate Kim, Yun Ju Sung, et al. Organ aging signatures in the plasma proteome track health and disease. *Nature*, 624(7990):164–172, 2023.

[150] Gaël Varoquaux and Veronika Cheplygina. Machine learning for medical imaging: methodological failures and recommendations for the future. *NPJ digital medicine*, 5(1):48, 2022.

[151] Michelle Chua, Doyun Kim, Jongmun Choi, Nahyoung G Lee, Vikram Deshpande, Joseph Schwab, Michael H Lev, Ramon G Gonzalez, Michael S Gee, and Synho Do. Tackling prediction uncertainty in machine learning for healthcare. *Nature Biomedical Engineering*, 7(6):711–718, 2023.

[152] Lucas Paulo de Lima Camillo. pyaging: a python-based compendium of gpu-optimized aging clocks. *Bioinformatics*, page btae200, 2024.

[153] Lisa O'Leary, Laura Hughes-McCormack, Kirsty Dunn, and Sally-Ann Cooper. Early death and causes of death of people with down syndrome: a systematic review. *Journal of Applied Research in Intellectual Disabilities*, 31(5):687–708, 2018.

[154] Scott D Landes, J Dalton Stevens, and Margaret A Turk. Cause of death in adults with down syndrome in the united states. *Disability and health journal*, 13(4):100947, 2020.

[155] R Asaad Baksh, Sarah E Pape, Li F Chan, Aisha A Aslam, Martin C Gulliford, and Andre Strydom. Multiple morbidity across the lifespan in people with down syndrome or intellectual disabilities: a population-based cohort study using electronic health records. *The Lancet Public Health*, 8(6):e453–e462, 2023.

[156] Angela P Presson, Ginger Partyka, Kristin M Jensen, Owen J Devine, Sonja A Rasmussen, Linda L McCabe, and Edward RB McCabe. Current estimate of down syndrome population prevalence in the united states. *The Journal of pediatrics*, 163(4):1163–1168, 2013.

[157] Mark Olfson, Tobias Gerhard, Cecilia Huang, Stephen Crystal, and T Scott Stroup. Premature mortality among adults with schizophrenia in the united states. *JAMA psychiatry*, 72(12):1172–1181, 2015.

[158] Padraig Oakley, Steve Kisely, Amanda Baxter, Meredith Harris, Jocelyne Desoe, Alyona Dziouba, and Dan Siskind. Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis. *Journal of psychiatric research*, 102: 245–253, 2018.

[159] Nicholas Chak Lam Yung, Corine Sau Man Wong, Joe Kwun Nam Chan, Eric Yu Hai Chen, and Wing Chung Chang. Excess mortality and life-years lost in people with schizophrenia and other non-affective psychoses: an 11-year population-based cohort study. *Schizophrenia Bulletin*, 47(2):474–484, 2021.

[160] Ming Yu, William D Hazelton, Georg E Luebeck, and William M Grady. Epigenetic aging: more than just a clock when it comes to cancer. *Cancer research*, 80(3):367–374, 2020.

[161] Qiong Lin and Wolfgang Wagner. Epigenetic aging signatures are coherently modified in cancer. *PLoS genetics*, 11(6):e1005334, 2015.

[162] Manuel H Aguiar-Oliveira and Andrzej Bartke. Growth hormone deficiency: health and longevity. *Endocrine reviews*, 40(2):575–601, 2019.

[163] Weihua Chen, Zeya Li, Yu Zhao, Yitian Chen, and Rongchong Huang. Global and national burden of atherosclerosis from 1990 to 2019: trend analysis based on the global burden of disease study 2019. *Chin. Med. J. (Engl.)*, 136(20):2442–2450, October 2023.

[164] João Costa, Joana Alarcão, Francisco Araujo, Raquel Ascenção, Daniel Caldeira, Francesca Fiorentino, Victor Gil, Miguel Gouveia, Francisco Lourenço, Alberto Mello E Silva, Filipa Sampaio, António Vaz Carneiro, and Margarida Borges. The burden of atherosclerosis in portugal. *Eur. Heart J. Qual. Care Clin. Outcomes*, 7(2):154–162, March 2021.

[165] Yoshiyuki Ikeda and Mitsuru Ohishi. Years of life lost analysis may promote governmental policy to prevent atherosclerotic cardiovascular disease. *Circ. J.*, 83(5):965–966, April 2019.

[166] B Lernfelt, M Forsberg, C Blomstrand, D Mellström, and R Volkmann. Cerebral atherosclerosis as predictor of stroke and mortality in representative elderly population. *Stroke*, 33(1):224–229, January 2002.

[167] K Sutton-Tyrrell, H G Alcorn, H Herzog, S F Kelsey, and L H Kuller. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. *Stroke*, 26(8):1319–1324, August 1995.

[168] Seth S Martin, Aaron W Aday, Zaid I Almarzooq, Cheryl A M Anderson, Pankaj Arora, Christy L Avery, Carissa M Baker-Smith, Bethany Barone Gibbs, Andrea Z Beaton, Amelia K Boehme, Yvonne Commodore-Mensah, Maria E Currie, Mitchell S V Elkind, Kelly R Evenson, Giuliano Generoso, Debra G Heard, Swapnil Hiremath, Michelle C Johansen, Rizwan Kalani, Dhruv S Kazi, Darae Ko, Junxiu Liu, Jared W Magnani, Erin D Michos, Michael E Mussolino, Sankar D Navaneethan, Nisha I Parikh, Sarah M Perman, Remy Poudel, Mary Rezk-Hanna, Gregory A Roth, Nilay S Shah, Marie-Pierre St-Onge, Evan L Thacker, Connie W Tsao, Sarah M Urbut, Harriette G C Van Spall, Jenifer H Voeks,

Nae-Yuh Wang, Nathan D Wong, Sally S Wong, Kristine Yaffe, Latha P Palaniappan, and American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: A report of US and global data from the american heart association. *Circulation*, 149(8):e347–e913, February 2024.

[169] Haijiang Dai, Arsalan Abu Much, Elad Maor, Elad Asher, Arwa Younis, Yawen Xu, Yao Lu, Xinyao Liu, Jingxian Shu, and Nicola Luigi Bragazzi. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the global burden of disease study 2017. *Eur. Heart J. Qual. Care Clin. Outcomes*, 8(1):50–60, January 2022.

[170] Adam Hartley, Dominic C Marshall, Justin D Salciccioli, Markus B Sikkel, Mahiben Maruthappu, and Joseph Shalhoub. Trends in mortality from ischemic heart disease and cerebrovascular disease in europe: 1980 to 2009. *Circulation*, 133(20):1916–1926, May 2016.

[171] Paola Bertuccio, Fabio Levi, Francesca Lucchini, Liliane Chatenoud, Cristina Bosetti, Eva Negri, and Carlo La Vecchia. Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in europe. *Eur. J. Cardiovasc. Prev. Rehabil.*, 18(4):627–634, August 2011.

[172] GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. *Lancet Neurol.*, 20(10): 795–820, October 2021.

[173] Ying Xian, Robert G Holloway, Wenqin Pan, and Eric D Peterson. Challenges in assessing hospital-level stroke mortality as a quality measure: comparison of ischemic, intracerebral hemorrhage, and total stroke mortality rates. *Stroke*, 43(6):1687–1690, June 2012.

[174] Rebbeca A Grysiewicz, Kurian Thomas, and Dilip K Pandey. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. *Neurol. Clin.*, 26(4):871–95, vii, November 2008.

[175] Ibadete Bytyçi and Gani Bajraktari. Mortality in heart failure patients. *Anatol. J. Cardiol.*, 15(1):63–68, January 2015.

[176] Eyal Shahar, Seungmin Lee, Joseph Kim, Sue Duval, Cheryl Barber, and Russell V Luepker. Hospitalized heart failure: rates and long-term mortality. *J. Card. Fail.*, 10(5):374–379, October 2004.

[177] Emily M Bucholz, Sharon-Lise T Normand, Yun Wang, Shuangge Ma, Haiqun Lin, and Harlan M Krumholz. Life expectancy and years of potential life lost after acute myocardial infarction by sex and race: A cohort-based study of medicare beneficiaries. *J. Am. Coll. Cardiol.*, 66(6):645–655, August 2015.

[178] Lotte Saaby, Tina Svenstrup Poulsen, Axel Cosmus Pyndt Diederichsen, Susanne Hosbond, Torben Bjerregaard Larsen, Henrik Schmidt, Oke Gerke, Jesper Hallas, Kristian Thygesen, and Hans Mickley. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. *Am. J. Med.*, 127 (4):295–302, April 2014.

[179] Dana Duricova, Natalia Pedersen, Margarita Elkjaer, Michael Gamborg, Pia Munkholm, and Tine Jess. Overall and cause-specific mortality in crohn's disease: a meta-analysis of population-based studies. *Inflamm. Bowel Dis.*, 16(2):347–353, February 2010.

[180] C Canavan, K R Abrams, and J F Mayberry. Meta-analysis: mortality in crohn's disease. *Aliment. Pharmacol. Ther.*, 25(8):861–870, April 2007.

[181] Catherine Dong, Marie Metzger, Einar Holsbø, Vittorio Perduca, and Franck Carbonnel. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. *Aliment. Pharmacol. Ther.*, 51(1): 8–33, January 2020.

[182] S Gyde, P Prior, M J Dew, V Saunders, J A Waterhouse, and R N Allan. Mortality in ulcerative colitis. *Gastroenterology*, 83(1 Pt 1):36–43, July 1982.

[183] M Ellen Kuenzig, Douglas G Manuel, Jessy Donelle, and Eric I Benchimol. Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. *CMAJ*, 192(45):E1394–E1402, November 2020.

[184] Christian P Selinger and Rupert W Leong. Mortality from inflammatory bowel diseases. *Inflamm. Bowel Dis.*, 18(8):1566–1572, August 2012.

[185] Tim Card, Richard Hubbard, and Richard F A Logan. Mortality in inflammatory bowel disease: a population-based cohort study. *Gastroenterology*, 125(6):1583–1590, December 2003.

23

[186] Adam Trickey, Caroline A Sabin, Greer Burkholder, Heidi Crane, Antonella d'Arminio Monforte, Matthias Egger, M John Gill, Sophie Grabar, Jodie L Guest, Inma Jarrin, Fiona C Lampe, Niels Obel, Juliana M Reyes, Christoph Stephan, Timothy R Sterling, Ramon Teira, Giota Touloumi, Jan-Christian Wasmuth, Ferdinand Wit, Linda Wittkop, Robert Zangerle, Michael J Silverberg, Amy Justice, and Jonathan A C Sterne. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in europe and north america: a collaborative analysis of cohort studies. *Lancet HIV*, 10(5):e295–e307, May 2023.

[187] Rebecca A Legarth, Magnus G Ahlström, Gitte Kronborg, Carsten S Larsen, Court Pedersen, Gitte Pedersen, Rajesh Mohey, Jan Gerstoft, and Niels Obel. Long-term mortality in HIV-infected individuals 50 years or older: A nationwide, population-based cohort study. *J. Acquir. Immune Defic. Syndr.*, 71(2): 213–218, February 2016.

[188] Margaret T May, Mark Gompels, Valerie Delpech, Kholoud Porter, Chloe Orkin, Stephen Kegg, Phillip Hay, Margaret Johnson, Adrian Palfreeman, Richard Gilson, David Chadwick, Fabiola Martin, Teresa Hill, John Walsh, Frank Post, Martin Fisher, Jonathan Ainsworth, Sophie Jose, Clifford Leen, Mark Nelson, Jane Anderson, Caroline Sabin, and UK Collaborative HIV Cohort (UK CHIC) Study. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. *AIDS*, 28(8):1193–1202, May 2014.

[189] Fumiyo Nakagawa, Margaret May, and Andrew Phillips. Life expectancy living with HIV: recent estimates and future implications. *Curr. Opin. Infect. Dis.*, 26(1):17–25, February 2013.

[190] Changrong Ke, Juanjuan Liang, Mi Liu, Shiwei Liu, and Chunping Wang. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. *BMC Nephrol.*, 23(1):17, January 2022.

[191] Marcello Tonelli, Natasha Wiebe, Bruce Culleton, Andrew House, Chris Rabbat, Mei Fok, Finlay McAlister, and Amit X Garg. Chronic kidney disease and mortality risk: a systematic review. *J. Am. Soc. Nephrol.*, 17(7):2034–2047, July 2006.

[192] Kyeong Min Kim, Hyung Jung Oh, Hyung Yun Choi, Hajeong Lee, and Dong-Ryeol Ryu. Impact of chronic kidney disease on mortality: A nationwide cohort study. *Kidney Res. Clin. Pract.*, 38(3):382–390, September 2019.

[193] Adam C Sheka, Oyedele Adeyi, Julie Thompson, Bilal Hameed, Peter A Crawford, and Sayeed Ikramuddin. Nonalcoholic steatohepatitis: A review. *JAMA*, 323(12):1175–1183, March 2020.

[194] Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan, and Miriam B Vos. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology*, 69(6): 2672–2682, June 2019.

[195] Mehmet Sayiner, Pegah Golabi, Maria Stepanova, Issah Younossi, Fatema Nader, Andrei Racila, and Zobair M Younossi. Primary biliary cholangitis in medicare population: The impact on mortality and resource use. *Hepatology*, 69(1):237–244, January 2019.

[196] Ana Lleo, Peter Jepsen, Emanuela Morenghi, Marco Carbone, Luca Moroni, Pier Maria Battezzati, Mauro Podda, Ian R Mackay, M Eric Gershwin, and Pietro Invernizzi. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. *Sci. Rep.*, 6:25906, May 2016.

[197] Tim R Card, Masoud Solaymani-Dodaran, and Joe West. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. *J. Hepatol.*, 48(6):939–944, June 2008.

[198] D Kornfeld, A Ekbom, and T Ihre. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. a population-based study. *Scand. J. Gastroenterol.*, 32(10):1042–1045, October 1997.

[199] Shiyu Xiao, Wenhui Xie, Yinghui Zhang, Lei Lei, and Yan Pan. Changing epidemiology of cirrhosis from 2010 to 2019: results from the global burden disease study 2019. *Ann. Med.*, 55(2):2252326, 2023.

[200] Annette Dam Fialla, Ove B Schaffalitzky de Muckadell, and Annmarie Touborg Lassen. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. *Scand. J. Gastroenterol.*, 47(6): 702–709, June 2012.

[201] Cari M Kitahara, Alan J Flint, Amy Berrington de Gonzalez, Leslie Bernstein, Michelle Brotzman, Robert J MacInnis, Steven C Moore, Kim Robien, Philip S Rosenberg, Pramil N Singh, Elisabete Weiderpass, Hans Olov Adami, Hoda Anton-Culver, Rachel Ballard-Barbash, Julie E Buring, D Michal Freedman, Gary E Fraser, Laura E Beane Freeman, Susan M Gapstur, John Michael Gaziano, Graham G Giles, Niclas Håkansson, Jane A Hoppin, Frank B Hu, Karen Koenig, Martha S Linet, Yikyung Park, Alpa V Patel, Mark P Purdue, Catherine Schairer, Howard D Sesso, Kala Visvanathan, Emily White, Alicja Wolk, Anne Zeleniuch-Jacquotte, and Patricia Hartge. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. *PLoS Med.*, 11(7):e1001673, July 2014.

[202] Ryan K Masters, Eric N Reither, Daniel A Powers, Y Claire Yang, Andrew E Burger, and Bruce G Link. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. *Am. J. Public Health*, 103(10):1895–1901, October 2013.

[203] Kevin R Fontaine, David T Redden, Chenxi Wang, Andrew O Westfall, and David B Allison. Years of life lost due to obesity. *JAMA*, 289(2):187–193, January 2003.

[204] C G Solomon and J E Manson. Obesity and mortality: a review of the epidemiologic data. *Am. J. Clin. Nutr.*, 66(4 Suppl):1044S–1050S, October 1997.

[205] Paz L D Ruiz, Lei Chen, Jedidiah I Morton, Agus Salim, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Manel Mata-Cases, Didac Mauricio, Gregory A Nichols, Santa Pildava, Stephanie H Read, Sarah H Wild, Jonathan E Shaw, and Dianna J Magliano. Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts. *Diabetologia*, 65(6):964–972, June 2022.

[206] Adrian H Heald, Mike Stedman, Mark Davies, Mark Livingston, Ramadan Alshames, Mark Lunt, Gerry Rayman, and Roger Gadsby. Estimating life years lost to diabetes: outcomes from analysis of national diabetes audit and office of national statistics data. *Cardiovasc. Endocrinol. Metab.*, 9(4):183–185, December 2020.

[207] Araz Rawshani, Naveed Sattar, Stefan Franzén, Aidin Rawshani, Andrew T Hattersley, Ann-Marie Svensson, Björn Eliasson, and Soffia Gudbjörnsdottir. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. *Lancet*, 392(10146):477–486, August 2018.

[208] Lili Huo, Jessica L Harding, Anna Peeters, Jonathan E Shaw, and Dianna J Magliano. Life expectancy of type 1 diabetic patients during 1997-2010: a national australian registry-based cohort study. *Diabetologia*, 59(6):1177–1185, June 2016.

[209] Shona J Livingstone, Daniel Levin, Helen C Looker, Robert S Lindsay, Sarah H Wild, Nicola Joss, Graham Leese, Peter Leslie, Rory J McCrimmon, Wendy Metcalfe, John A McKnight, Andrew D Morris, Donald W M Pearson, John R Petrie, Sam Philip, Naveed A Sattar, Jamie P Traynor, Helen M Colhoun, Scottish Diabetes Research Network epidemiology group, and Scottish Renal Registry. Estimated life expectancy in a scottish cohort with type 1 diabetes, 2008-2010. *JAMA*, 313(1):37–44, January 2015.

[210] Valma Harjutsalo, Carol Forsblom, and Per-Henrik Groop. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. *BMJ*, 343(sep08 2):d5364, September 2011.

[211] Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. *Lancet Diabetes Endocrinol.*, 11(10):731–742, October 2023.

[212] Rongrong Zhu, Shan Zhou, Liang Xia, and Xiaoming Bao. Incidence, morbidity and years lived with disability due to type 2 diabetes mellitus in 204 countries and territories: Trends from 1990 to 2019. *Front. Endocrinol. (Lausanne)*, 13:905538, July 2022.

[213] Alison K Wright, Evangelos Kontopantelis, Richard Emsley, Iain Buchan, Naveed Sattar, Martin K Rutter, and Darren M Ashcroft. Life expectancy and cause-specific mortality in type 2 diabetes: A population-based cohort study quantifying relationships in ethnic subgroups. *Diabetes Care*, 40(3):338–345, March 2017.

[214] H E Mulnier, H E Seaman, V S Raleigh, S S Soedamah-Muthu, H M Colhoun, and R A Lawrenson. Mortality in people with type 2 diabetes in the UK. *Diabet. Med.*, 23(5):516–521, May 2006.

[215] Aki Juhani Käräjämäki, Arto Korkiakoski, Janne Hukkanen, Y Antero Kesäniemi, and Olavi Ukkola. Long-term metabolic fate and mortality in obesity without metabolic syndrome. *Ann. Med.*, 54(1):1432–1443, December 2022.

[216] Sheng Hui Wu, Zhong Liu, and Suzanne C Ho. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. *Eur. J. Epidemiol.*, 25(6):375–384, June 2010.

[217] Dariush Mozaffarian, Aruna Kamineni, Ronald J Prineas, and David S Siscovick. Metabolic syndrome and mortality in older adults: the cardiovascular health study. *Arch. Intern. Med.*, 168(9):969–978, May 2008.

[218] Jane Xu, Ching S Wan, Kiriakos Ktoris, Esmee M Reijnierse, and Andrea B Maier. Sarcopenia is associated with mortality in adults: A systematic review and meta-analysis. *Gerontology*, 68(4):361–376, 2022.

[219] Justin C Brown, Michael O Harhay, and Meera N Harhay. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. *J. Cachexia Sarcopenia Muscle*, 7(3):290–298, June 2016.

[220] Shu-Fang Chang and Pei-Ling Lin. Systematic literature review and meta-analysis of the association of sarcopenia with mortality. *Worldviews Evid. Based. Nurs.*, 13(2):153–162, April 2016.

[221] Asma Rashki Kemmak, Aziz Rezapour, Reza Jahangiri, Shima Nikjoo, Hiro Farabi, and Samira Soleiman-pour. Economic burden of osteoporosis in the world: A systematic review. *Med. J. Islam. Repub. Iran*, 34:154, November 2020.

[222] Bo Abrahamsen, Clive Osmond, and Cyrus Cooper. Life expectancy in patients treated for osteoporosis: Observational cohort study using national danish prescription data. *J. Bone Miner. Res.*, 30(9):1553–1559, September 2015.

[223] J R Center, T V Nguyen, D Schneider, P N Sambrook, and J A Eisman. Mortality after all major types of osteoporotic fracture in men and women: an observational study. *Lancet*, 353(9156):878–882, March 1999.

[224] N Cherny, R Catane, D Schrijvers, M Kloke, and F Strasser. European society for medical oncology (ESMO) program for the integration of oncology and palliative care: a 5-year review of the designated centers' incentive program. *Ann. Oncol.*, 21(2):362–369, February 2010.

[225] Minbo Liu, Fang Jin, Xiaocong Yao, and Zhongxin Zhu. Disease burden of osteoarthritis of the knee and hip due to a high body mass index in china and the USA: 1990-2019 findings from the global burden of disease study 2019. *BMC Musculoskelet. Disord.*, 23(1):63, January 2022.

[226] Ming Fu, Hongming Zhou, Yushi Li, Hai Jin, and Xiqing Liu. Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 global burden of disease study. *Arthritis Res. Ther.*, 24(1):8, January 2022.

[227] Q Liu, J Niu, J Huang, Y Ke, X Tang, X Wu, R Li, H Li, X Zhi, K Wang, Y Zhang, and J Lin. Knee osteoarthritis and all-cause mortality: the wuchuan osteoarthritis study. *Osteoarthritis Cartilage*, 23(7):1154–1157, July 2015.

[228] Ying-Ming Chiu, Yi-Peng Lu, Joung-Liang Lan, Der-Yuan Chen, and Jung-Der Wang. Lifetime risks, life expectancy, and health care expenditures for rheumatoid arthritis: A nationwide cohort followed up from 2003 to 2016. *Arthritis Rheumatol.*, 73(5):750–758, May 2021.

[229] Yuqing Zhang, Na Lu, Christine Peloquin, Maureen Dubreuil, Tuhina Neogi, J Antonio Aviña-Zubieta, Sharan K Rai, and Hyon K Choi. Improved survival in rheumatoid arthritis: a general population-based cohort study. *Ann. Rheum. Dis.*, 76(2):408–413, February 2017.

[230] M N Lassere, J Rappo, I J Portek, A Sturgess, and J P Edmonds. How many life years are lost in patients with rheumatoid arthritis? secular cause-specific and all-cause mortality in rheumatoid arthritis, and their predictors in a long-term australian cohort study. *Intern. Med. J.*, 43(1):66–72, January 2013.

[231] L T Jacobsson, W C Knowler, S Pillemer, R L Hanson, D J Pettitt, R G Nelson, A del Puente, D R McCance, M A Charles, and P H Bennett. Rheumatoid arthritis and mortality. a longitudinal study in pima indians. *Arthritis Rheum.*, 36(8):1045–1053, August 1993.

[232] Xue Li, Xiaojin Feng, Xiaodong Sun, Ningning Hou, Fang Han, and Yongping Liu. Global, regional, and national burden of alzheimer's disease and other dementias, 1990-2019. *Front. Aging Neurosci.*, 14:937486, October 2022.

[233] Chih-Sung Liang, Dian-Jeng Li, Fu-Chi Yang, Ping-Tao Tseng, Andre F Carvalho, Brendon Stubbs, Trevor Thompson, Christoph Mueller, Jae Il Shin, Joaquim Radua, Robert Stewart, Tarek K Rajji, Yu-Kang Tu, Tien-Yu Chen, Ta-Chuan Yeh, Chia-Kuang Tsai, Chia-Ling Yu, Chih-Chuan Pan, and Che-Sheng Chu. Mortality rates in alzheimer's disease and non-alzheimer's dementias: a systematic review and meta-analysis. *Lancet Healthy Longev.*, 2(8):e479–e488, August 2021.

[234] Mary Ganguli, Hiroko H Dodge, Changyu Shen, Rajesh S Pandav, and Steven T DeKosky. Alzheimer disease and mortality: a 15-year epidemiological study. *Arch. Neurol.*, 62(5):779–784, May 2005.

[235] Hiroko H Dodge, Changyu Shen, Rajesh Pandav, Steven T DeKosky, and Mary Ganguli. Functional transitions and active life expectancy associated with alzheimer disease. *Arch. Neurol.*, 60(2):253–259, February 2003.

[236] Angus D Macleod, Kate S M Taylor, and Carl E Counsell. Mortality in parkinson's disease: a systematic review and meta-analysis. *Mov. Disord.*, 29(13):1615–1622, November 2014.

[237] Allison W Willis, Mario Schootman, Nathan Kung, Bradley A Evanoff, Joel S Perlmutter, and Brad A Racette. Predictors of survival in patients with parkinson disease. *Arch. Neurol.*, 69(5):601–607, May 2012.

[238] Ignacio J Posada, Julián Benito-León, Elan D Louis, Rocío Trincado, Alberto Villarejo, María José Medrano, and Félix Bermejo-Pareja. Mortality from parkinson's disease: a population-based prospective study (NEDICES). *Mov. Disord.*, 26(14):2522–2529, December 2011.

[239] Zhen Qian, Yuancun Li, Zhiqiang Guan, Pi Guo, Ke Zheng, Yali Du, Shengjie Yin, Binyao Chen, Hongxi Wang, Jiao Jiang, Kunliang Qiu, and Mingzhi Zhang. Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. *Front. Public Health*, 11: 1073278, February 2023.

[240] Hanne Marie Bøe Lunde, Jörg Assmus, Kjell-Morten Myhr, Lars Bø, and Nina Grytten. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. *J. Neurol. Neurosurg. Psychiatry*, 88(8):621–625, August 2017.

[241] Emmanuelle Leray, Sandra Vukusic, Marc Debouverie, Michel Clanet, Bruno Brochet, Jérôme de Sèze, Hélène Zéphir, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Pierre Clavelou, Jean Pelletier, Eric Berger, Philippe Cabre, Jean-Philippe Camdessanché, Shoshannah Kalson-Ray, Christian Confavreux, and Gilles Edan. Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: Data from a large-scale french observational study. *PLoS One*, 10(7):e0132033, July 2015.

[242] Chih-Sung Liang, Dian-Jeng Li, Fu-Chi Yang, Ping-Tao Tseng, Andre F Carvalho, Brendon Stubbs, Trevor Thompson, Christoph Mueller, Jae Il Shin, Joaquim Radua, Robert Stewart, Tarek K Rajji, Yu-Kang Tu, Tien-Yu Chen, Ta-Chuan Yeh, Chia-Kuang Tsai, Chia-Ling Yu, Chih-Chuan Pan, and Che-Sheng Chu. Mortality rates in alzheimer's disease and non-alzheimer's dementias: a systematic review and meta-analysis. *Lancet Healthy Longev.*, 2(8):e479–e488, August 2021.

[243] Christoph Mueller, Pinar Soysal, Arvid Rongve, Ahmet Turan Isik, Trevor Thompson, Stefania Maggi, Lee Smith, Cristina Basso, Robert Stewart, Clive Ballard, John T O'Brien, Dag Aarsland, Brendon Stubbs, and Nicola Veronese. Survival time and differences between dementia with lewy bodies and alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. *Ageing Res. Rev.*, 50:72–80, March 2019.

[244] Annabel Price, Redwan Farooq, Jin-Min Yuan, Vandana B Menon, Rudolf N Cardinal, and John T O'Brien. Mortality in dementia with lewy bodies compared with alzheimer's dementia: a retrospective naturalistic cohort study. *BMJ Open*, 7(11):e017504, November 2017.

[245] Yoshito Nishimura, Ko Harada, Toshihiro Koyama, Hideharu Hagiya, and Fumio Otsuka. A nationwide trend analysis in the incidence and mortality of Creutzfeldt-Jakob disease in japan between 2005 and 2014. *Sci. Rep.*, 10(1):15509, September 2020.

[246] Franc Llorens, Nicole Rübsamen, Peter Hermann, Matthias Schmitz, Anna Villar-Piqué, Stefan Goebel, André Karch, and Inga Zerr. A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease. *Alzheimers. Dement.*, 16(10):1438–1447, October 2020.

[247] Ellen Gelpi, Harald Heinzl, Romana Hoftberger, Ursula Unterberger, Thomas Strobel, Till Voigtlander, Edita Drobna, Christa Jarius, Susanna Lang, Thomas Waldhor, Hanno Bernheimer, and Herbert Budka. Creutzfeldt-Jakob disease in austria: an autopsy-controlled study. *Neuroepidemiology*, 30(4):215–221, April 2008.

[248] Seon Cheol Park, Dong Wook Kim, Eun Cheol Park, Cheung Soo Shin, Chin Kook Rhee, Young Ae Kang, and Young Sam Kim. Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study. *Korean J. Intern. Med.*, 34(6):1272–1278, November 2019.

[249] Lisa Ruvuna and Akshay Sood. Epidemiology of chronic obstructive pulmonary disease. *Clin. Chest Med.*, 41(3):315–327, September 2020.

[250] Peter Lange, Yunus Çolak, Truls Sylvan Ingebrigtsen, Jørgen Vestbo, and Jacob Louis Marott. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the copenhagen city heart study: a prospective population-based analysis. *Lancet Respir. Med.*, 4(6):454–462, June 2016.

[251] Lisa Lancaster, Francesco Bonella, Yoshikazu Inoue, Vincent Cottin, James Siddall, Mark Small, and Jonathan Langley. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. *Respirology*, 27(1):66–75, January 2022.

[252] John P Hutchinson, Tricia M McKeever, Andrew W Fogarty, Vidya Navaratnam, and Richard B Hubbard. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. *Ann. Am. Thorac. Soc.*, 11(8):1176–1185, October 2014.

[253] Martin Kolb and Harold R Collard. Staging of idiopathic pulmonary fibrosis: past, present and future. *Eur. Respir. Rev.*, 23(132):220–224, June 2014.

[254] Evans R Fernández Pérez, Craig E Daniels, Darrell R Schroeder, Jennifer St Sauver, Thomas E Hartman, Brian J Bartholmai, Eunhee S Yi, and Jay H Ryu. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. *Chest*, 137(1):129–137, January 2010.

[255] Nicolas A Menzies, Matthew Quaife, Brian W Allwood, Anthony L Byrne, Anna K Coussens, Anthony D Harries, Florian M Marx, Jamilah Meghji, Debora Pedrazzoli, Joshua A Salomon, Sedona Sweeney, Sanne C van Kampen, Robert S Wallis, Rein M G J Houben, and Ted Cohen. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. *Lancet Glob. Health*, 9(12):e1679–e1687, December 2021.

[256] Christian Lee-Rodriguez, Paul Y Wada, Yun-Yi Hung, and Jacek Skarbinski. Association of mortality and years of potential life lost with active tuberculosis in the united states. *JAMA Netw. Open*, 3(9):e2014481, September 2020.

[257] Franziska Schnabel, Uwe Kornak, and Bernd Wollnik. Premature aging disorders: A clinical and genetic compendium. *Clin. Genet.*, 99(1):3–28, January 2021.

[258] Junko Oshima and Fuki M Hisama. Search and insights into novel genetic alterations leading to classical and atypical werner syndrome. *Gerontology*, 60(3):239–246, January 2014.

[259] M Goto. Hierarchical deterioration of body systems in werner's syndrome: implications for normal ageing. *Mech. Ageing Dev.*, 98(3):239–254, December 1997.

[260] Raoul C M Hennekam. Hutchinson-Gilford progeria syndrome: review of the phenotype. *Am. J. Med. Genet. A*, 140(23):2603–2624, December 2006.

[261] Josivan Gomes Lima, Lucia Helena C Nobrega, Natalia Nobrega Lima, Marcel Catão Ferreira Dos Santos, Pedro Henrique Dantas Silva, Maria de Fatima P Baracho, Debora Nobrega Lima, Julliane Tamara Araújo de Melo Campos, Leonardo Capistrano Ferreira, Francisco Paulo Freire Neto, Carolina de O Mendes-Aguiar, and Selma Maria B Jeronimo. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. *PLoS One*, 13(6):e0199052, June 2018.

[262] M Seip and O Trygstad. Generalized lipodystrophy, congenital and acquired (lipoatrophy). *Acta Paediatr. Suppl.*, 413:2–28, June 1996.

[263] Mohammed Al Nuaimi, Evelyn Elias, Albert Catala, Bozana Zlateska, Yeon Jung Lim, Robert J Klaassen, Geoff DE Cuvelier, Conrad Fernandez, Meera Rayar, MacGregor Steele, et al. Genotypic and phenotypic spectrum of dyskeratosis congenita: Results from the canadian inherited marrow failure registry. *Blood*, 136:8–9, 2020.

[264] Alex Zhavoronkov, Kirill Kochetov, Peter Diamandis, and Maria Mitina. Psychoage and subjage: development of deep markers of psychological and subjective age using artificial intelligence. *Aging (Albany NY)*, 12(23):23548, 2020.

28

[265] Francesco Morandini, Cheyenne Rechsteiner, Kevin Perez, Viviane Praz, Guillermo Lopez Garcia, Laura C Hinte, Ferdinand von Meyenn, and Alejandro Ocampo. Atac-clock: An aging clock based on chromatin accessibility. *GeroScience*, 46(2):1789–1806, 2024.

[266] Sanish Sathyan, Emmeline Ayers, Tina Gao, Erica F Weiss, Sofiya Milman, Joe Verghese, and Nir Barzilai. Plasma proteomic profile of age, health span, and all-cause mortality in older adults. *Aging Cell*, 19(11): e13250, 2020.

[267] Jonathan Q Purnell. Definitions, classification, and epidemiology of obesity. In Kenneth R Feingold, Bradley Anawalt, Marc R Blackman, Alison Boyce, George Chrousos, Emiliano Corpas, Wouter W de Herder, Ketan Dhatariya, Kathleen Dungan, Johannes Hofland, Sanjay Kalra, Gregory Kaltsas, Nitin Kapoor, Christian Koch, Peter Kopp, Márta Korbonits, Christopher S Kovacs, Wendy Kuohung, Blandine Laferrère, Miles Levy, Elizabeth A McGee, Robert McLachlan, Maria New, Jonathan Purnell, Rakesh Sahay, Amy S Shah, Frederick Singer, Mark A Sperling, Constantine A Stratakis, Dace L Trence, and Don P Wilson, editors, *Endotext*. MDText.com, Inc., South Dartmouth (MA), 5 2023.

[268] Bradley Busebee, Wissam Ghusn, Lizeth Cifuentes, and Andres Acosta. Obesity: A review of pathophysiology and classification. In *Mayo Clinic Proceedings*. Elsevier, 2023.

[269] Pan Du, Xiao Zhang, Chiang-Ching Huang, Nadereh Jafari, Warren A Kibbe, Lifang Hou, and Simon M Lin. Comparison of beta-value and m-value methods for quantifying methylation levels by microarray analysis. *BMC bioinformatics*, 11:1–9, 2010.

A   Appendix

A.1   Limitations

The current version of our benchmark harbors several important limitations. First, some selected conditions might not actually fulfill the suggested criteria, especially regarding their effect on blood DNA methylation, although we did our best to identify the most unambiguous ones. From the other hand, some conditions that fit our criteria might have escaped our attention. Second, the conditions are not represented uniformly, with some being featured in 10+ datasets (HIV, rheumatoid arthritis), and some present in a single dataset with few samples (ischemic heart disease, chronic obstructive pulmonary disease, congenital generalized lipodystrophy). The third limitation arises from the known issue of hidden subgroups of patients and mislabeled instances [150]. For the AAC cohorts, having hidden co-morbidities is acceptable, as they would supposedly exaggerate aging acceleration even stronger. Conversely, having severe, but unlabeled diseases in the HC cohort would likely substantially alter the findings of our benchmark. Unfortunately, we can neither expand our dataset to cover all conditions equally by mining solely the open-access data, nor explicitly confirm if all studies at hand comply with our requirements.

A.2   Future work

We plan to further extend our benchmarking dataset by incorporating open access data of additional modalities, such as clinical biochemistry, transcriptomics, proteomics, metabolomics, etc. To overcome the aforementioned limitations, we strongly urge an open discussion on developing a panel of conditions and datasets that would serve as the gold standard for reliable and comprehensive validation of emerging biomarkers of aging. We also believe that it is important to expand the benchmark to animal models, since collecting the required data and developing preclinical biomarkers of aging in some animals is associated with fewer ethical and financial challenges. Hopefully, all these issues and developments will be addressed by the efforts of a recently established Biomarkers of Aging Consortium (https://www.agingconsortium.org/). Ultimately, the "correct" BA estimator should satisfy all four properties we defined in the Introduction. Regardless of the clock generation or data modality, reliable aging clock models must also be able to assess the uncertainty of their own predictions before being integrated in clinical trials [147, 151]. And indeed, an example of uncertainty-aware aging clocks has recently been proposed [28]. We also aim to upgrade our package to facilitate the interaction with other clock-related resources, including Biolearn [42] and pyaging [152].

A.3   Societal impact

The obvious positive societal impact of our work is the prospect of increased active lifespan and that of healthy longevity. Our benchmarking methodology assists in determining the most accurate predictors of the biological age, which, in turn, assists in delineating the crucial biomarkers and factors that might prolong the healthy life. The potential negative impact entails the common issues emphasized when a fundamental biological problem is tackled with the AI tools. Specific to the subject of longevity are the issues of pre-mature excitement in the mass media when a certain factor is hypothesized to prolong life. A relevant fraud in the pharmaceutical industry is also plausible, if not regulated. One could also envision the depletion of resources caused by an overpopulation of the Earth, which might happen if the longevity drug is found. These negative possibilities are not expected to be sudden and could be mitigated gradually – similarly to a plethora of other benchmarking works established for solving important biological problems.

A.4   Motivation behind including or excluding particular conditions

Our first criterion for selecting aging-accelerating conditions (AACs) was that having an AAC must lead to decreased life expectancy (LE) compared to the general population, even when treated with existing therapies. As we have mentioned earlier, this decrease in LE and the corresponding increase in mortality must result mainly from intrinsic organismal causes rather than from socioeconomic factors and self-destructive behaviors related to a given condition. Thus, while Down syndrome (DS) is associated with elevated prevalence of multiple chronic diseases [153–155], LE of DS individuals has grown dramatically by over 450% from 1960 to 2007 [156], even though no cure for DS has

been developed, suggesting strong non-biological confounding factors at play. Additionally, while some authors expect DS to display accelerated epigenetic aging [8], others anticipate deceleration when applying epigenetic clocks to DS blood samples, as DS individuals are hypothesized to feature juvenile blood [34]. Schizophrenia (SCZ) is another example of a controversial condition: while we can find increased incidence of age-related comorbidities such as cardiovascular diseases, cancers, or chronic obstructive pulmonary disease [157–159], the rates of suicide and substance-induced death are also increased in people with SCZ [157]. We therefore suggest excluding such ambiguous conditions from robust clock benchmarking, as it is currently difficult to disentangle functional organismal deterioration from external and behavioral condition-related confounders and evaluate the degree to which the latter influence LE.

Regarding cancers in general, it is difficult to formulate a pre-hoc hypothesis about the directionality of epigenetic age changes. Even though we know that DNAm can be used to create signatures of various cancers, and that changes in some DNAm sites are shared between aging and cancers [160], we cannot be certain that an aging clock would indicate accelerated aging in cancerous samples, as some cancer-specific and stem cell-like features such as telomere maintenance might prompt a clock model to treat it as a marker of partial rejuvenation. In support of these considerations, epigenetic age predictions were found to exhibit no correlation with multiple TCGA cancer types [161]. To avoid possible speculation as far as possible, we recommend excluding cancer from clock benchmarking, as it is difficult to hypothesize about clock performance in such complex phenomena.

Aging-decelerating condition (ADC) is defined as a condition that increases LE compared to the general population and features the same second and third criteria as an AAC. With respect to human data, however, the ADCs are difficult to determine, as human lifespan-increasing interventions are yet to emerge. There are genetic mutations, such as Laron syndrome (growth hormone insensitivity) or isolated growth hormone deficiency (growth hormone releasing hormone insensitivity), that appear to protect against some age-related pathologies, but they do not feature a prolonged lifespan [162]. To avoid dubious interpretation, we recommend omitting the inclusion of any condition into the ADC category when benchmarking human aging clocks.

The resulting list of condition classes and conditions selected to represent accelerated aging is listed in Table A1. Population-based evidence for condition inclusion and the number of datasets found and selected per condition are displayed in Table A2.

A.5 On data types used for aging clocks construction

Multiple data modalities were previously used for aging clocks construction. Some examples beyond DNA methylation data include also clinical blood samples [12], psycho-social questionnaires [264], facial images [13], urine metabolites [33], and different omics data, gene expression [14], DNA accessibility [265], plasma proteins [266], etc. Interestingly, DNA methylation data allow one the most accurate prediction of chronological age compared to other data modalities, second only to facial imaging data [21], and it continues to be used most widely in aging clock construction [10]. It is also important to note that from a practical point of view, in order to construct a clinically relevant aging clock, the method of obtaining the data should not be too invasive and heavy-handed. For this reason, many clock developers prefer using blood, saliva, or buccal epithelial samples as data sources.

A.6 Aging clocks included in the benchmarking

The full list of published aging clocks used in this analysis is provided in Table A3.

A.7 Comparison of different approaches to missing values imputation

We ran additional experiments (see Table A4) to test different imputation methods and observed that the method we used (SeSAMe 450k) leads to the most accurate age predictions across all models except the VidalBralo clock, whose MAE is 0.19% lower when using imputation by zeros. Notably, we did not have to impute all 800k+ sites in the whole dataset, as we only imputed sites included in each respective clock model. Most importantly, clock performance in other benchmarking tasks remained intact, regardless of the imputation strategies.

Table A1: Aging-accelerating conditions. ICD-10: class or condition code(s) from the International Classification of Diseases Version 10; a dash indicates lack of specific code; abbr.: abbreviation.

Condition class	Class ICD-10 code	Class abbr.	Aging-accelerating condition (AAC)	Condition ICD-10 code	Condition abbr.
Cardio-vascular diseases	I00-I99	CVD	Atherosclerosis	I70	AS
			Ischemic heart disease	I20-I25	IHD
			Cerebrovascular accident	I60-I63	CVA
			Heart failure	I50	HF
			Myocardial infarction	I21-I22	MCI
Immune system diseases	—	ISD	Inflammatory bowel disease	K50-K51	IBD
			Human immunodeficiency virus infection	B20-B24	HIV
Kidney diseases	N00-N99	KDD	Chronic kidney disease	N18	CKD
Liver diseases	K70-K77	LVD	Nonalcoholic steatohepatitis	K75.81	NASH
			Primary biliary cholangitis	K74.3	PBC
			Primary sclerosing cholangitis	K83.01	PSC
			Cirrhosis	K70.3, K74.3-K74.6	CIR
Metabolic diseases	E00-E90	MBD	Extreme obesity	E66.01, E66.2	XOB
			Type 1 diabetes	E10	T1D
			Type 2 diabetes	E11	T2D
			Metabolic syndrome	E88.810	MBS
Musculo-skeletal diseases	M00-M99	MSD	Sarcopenia	M62.84	SP
			Osteoporosis	M80-M81	OP
			Osteoarthritis	M15-M19	OA
			Rheumatoid arthritis	M05-M06	RA
Neuro-degenerative diseases	G00-G99	NDD	Alzheimer's disease	G30	AD
			Parkinson's disease	G20	PD
			Multiple sclerosis	G35	MS
			Dementia with Lewy bodies	G31.83	DLB
			Creutzfeldt-Jakob disease	A81.0	CJD
Respiratory diseases	J00-J99	RSD	Chronic obstructive pulmonary disease	J44	COPD
			Idiopathic pulmonary fibrosis	J84.112	IPF
			Tuberculosis	A15	TB
Progeroid syndromes	—	PGS	Werner syndrome	E34.8	WS
			Hutchinson-Gilford progeria syndrome	E34.8	HGPS
			Congenital generalized lipodystrophy	E88.1	CGL
			Dyskeratosis congenita	Q82.8	DKC

Table A2: Population-based evidence for condition inclusion, and the number of datasets found and selected for each condition. GEO: Gene Expression Omnibus database; abbr.: abbreviation.

Class abbr.	Condition abbr.	Evidence of decreased life expectancy and/or systemic effects	N items in the GEO query	N datasets after filtering
CVD	AS	[163–167]	22	3
	IHD	[168–171]	21	1
	CVA	[168, 172–174]	10	2
	HF	[168, 175, 176]	14	0
	MCI	[168, 177, 178]	19	0
ISD	IBD	[179–185]	30	4
	HIV	[168, 186–189]	44	15
KDD	CKD	[190–192]	6	0
LVD	NASH	[193, 194]	8	0
	PBC	[195, 196]	1	0
	PSC	[197, 198]	2	0
	CIR	[168, 199, 200]	68	0
MBD	XOB	[168, 201–204]	96	4
	T1D	[205–210]	14	1
	T2D	[168, 211–214]	45	1
	MBS	[168, 215–217]	17	0
MSD	SP	[218–220]	2	0
	OP	[221–224]	5	1
	OA	[168, 225–227]	26	0
	RA	[228–231]	37	10
NDD	AD	[168, 232–235]	43	2
	PD	[236–238]	37	6
	MS	[239–241]	29	8
	DLB	[242–244]	5	0
	CJD	[245–247]	1	1
RSD	COPD	[168, 248–250]	14	1
	IPF	[251–254]	14	0
	TB	[168, 255, 256]	13	3
PGS	WS	[257–259]	7	1
	HGPS	[257, 260]	14	1
	CGL	[261, 262]	1	1
	DKC	[263]	2	0
Total number of datasets			**667**	**66**

33

Table A3: Aging clock models tested in our benchmark.

Model name	N CpGs	Gene-ration	Extra parameters	Tissues used for training	Reference
Hannum	71	1	—	Blood	[15]
HorvathV1	353	1	—	Multi-tissue	[8]
Lin	99	1	—	Blood	[97]
VidalBralo	8	1	—	Blood	[98]
HorvathV2	391	1	—	Blood, Skin	[46]
PhenoAgeV1	513	2	—	Blood	[16]
Zhang19_EN	514	1	—	Blood, Saliva	[32]
GrimAgeV1	1030	2	Age, Sex	Blood	[17]
GrimAgeV2	1030	2	Age, Sex	Blood	[100]
PhenoAgeV2	959	2	—	Blood	[99]
YingAdaptAge	999	1	—	Blood	[19]
YingCausAge	585	1	—	Blood	[19]
YingDamAge	1089	1	—	Blood	[19]

Table A4: MAE results (in years) for different strategies of missing values imputation (sorted by increasing MAE when using SeSAMe 450k imputation).

Model name	SeSAMe 450k	Average	Zeros
HorvathV2	**4.143847**	4.701762	4.719477
HorvathV1	**5.350622**	5.475857	5.475857
GrimAgeV1	**7.462245**	8.102066	8.241653
Lin	**7.467559**	8.367630	8.429655
Hannum	**7.477633**	7.890421	7.907489
PhenoAgeV2	**7.604413**	8.439977	8.432397
PhenoAgeV1	**8.009677**	8.380239	8.381561
YingCausAge	**8.969959**	11.599078	11.551690
VidalBralo	9.124225	9.124387	**9.107015**
GrimAgeV2	**9.796544**	10.513198	10.576180
Zhang19_EN	**10.534452**	10.611938	10.611938
YingDamAge	**19.534224**	20.179561	20.211066
YingAdaptAge	**19.972273**	23.287544	23.353844

A.8 On accessibility of existing epigenetic mortality data

Although there are some existing biobanks that aggregate sensitive human data and provide them in an open-access manner, (e.g., NHANES: `https://wwwn.cdc.gov/nchs/nhanes/`), most biobanks rely on authorized access to their data (e.g., UK Biobank: `https://www.ukbiobank.ac.uk/`). The similar semi-open situation occurs with DNA methylation data. Here, we provide information about 12 cohort studies containing DNA methylation data and mortality/morbidity information simultaneously, but all of which allow downloading their data upon a reasonable request by contacting with the principal investigators of each cohort or by requesting data on a special platform. These studies include the Framingham Heart Study (FHS), the Women's Health Initiative (WHI), the Lothian Birth Cohorts (LBC), the Atherosclerosis Risk in Communities (ARIC), the Cardiovascular Health Study (CHS), the Normative Aging Study (NAS), the Invecchiare in Chianti (InCHIANTi), the Cooperative Health Research in the Region of Augsburg (KORA), the Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER), the Danish Twin Register sample (DTR), the Rotterdam Study (RS), and the Coronary Artery Risk Development in Young Adults (CARDIA) [1, 36]. While we recognize the risks associated with releasing sensitive patient data into the public domain, we also want to emphasize that comprehensive independent validation of the aging clock is difficult without these important datasets. The confidentiality of such data also does not allow us to use it as part of this open-access benchmark. Instead, we focused solely on those epigenetic datasets of patients with AACs distributed across human lifespan, which did not contain information on mortality, but was publicly accessible.

A.9 DNA methylation data collection

As we have mentioned in the Methodology section, dataset search was performed using the NCBI Gene Expression Omnibus (GEO) database, an unrestricted-access omics data repository (`https://www.ncbi.nlm.nih.gov/geo/`) which shares data using the Open Database License (ODbL). The resulting list of 66 AAC datasets [47–96] indicated in Table A2 is visualized in Figure 2E and includes: atherosclerosis (AS), ischemic heart disease (IHD, also known as coronary heart disease), cerebrovascular accident (CVA, also known as stroke), inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis), human immunodeficiency virus infection (HIV), extreme obesity (XOB, defined by having BMI $\geq$ 40 kg/m^2 [267, 268]; also known as class III obesity, severe obesity, or morbid obesity), type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2D), rheumatoid arthritis (RA), osteoporosis (OP), Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), Creutzfeldt-Jakob disease (CJD), chronic obstructive pulmonary disease (COPD), tuberculosis (TB), Werner syndrome (WS, including atypical Werner syndrome), Hutchinson-Gilford progeria syndrome (HGPS, including non-classical progeroid laminopathies), and congenital generalized lipodystrophy (CGL, also known as Berardinelli-Seip lipodystrophy). Age distribution across conditions is demonstrated in Figure A1. Overviews of all benchmarking and training (healthy controls only) datasets and their age distributions are provided in Figure A2 and Figure A3. The information on how patient consent was obtained and which ethics procedures were implemented can be accessed in the respective publications. As per NCBI GEO guidelines, all submitters must "ensure that the submitted information does not compromise participant privacy" (`https://www.ncbi.nlm.nih.gov/geo/info/faq.html`).

A.10 DNA methylation data processing

After pre-processing raw output from microarrays or sequencing machines, DNA methylation levels per site are reported quantitatively either as beta values, or as M values. Briefly, beta values represent the ratio of methylated signal (probe intensity or sequencing read counts) to total signal per site (sum of methylated and unmethylated probe intensities or sequencing read counts), while M value is the log2 ratio of the methylated signal versus an unmethylated signal. A more thorough comparison of the two measures can be found in Du et al. [269]. In the original datasets deposited on GEO, DNA methylation values were represented either as a beta fraction (ranging from 0 to 1), beta percentages (ranging from 0 to 100), or M-values (can be both negative and positive, equals 0 when beta equals 0.5). We converted all data to the beta-value fractions ranging from 0 to 1. The values outside this range were treated as missing values (NaNs), as they are not biological. In each dataset, only samples

Figure A1: Distribution of the benchmarking dataset samples per condition across ages.

that were relevant for benchmarking (that is, were annotated by age, tissue, and condition) were retained.

The resulting datasets meta-data contains the following fields: DatasetID (datasets GEO ID), PlatformID (GEO ID of a DNA methylation profiling platform), Tissue (sample source tissue: "Blood" stands for peripheral blood samples, "Saliva"—for saliva samples, and "Buccal"—for buccal swab samples), CellType (sample cell type: either a specific cell population, e.g., immune cell subtypes with cell type-specific molecular markers, or broader categories such as whole blood, buffy coat, peripheral blood mononuclear cells (PBMC), or peripheral blood leukocytes (PBL); some samples lack this annotation), Gender (abbreviated sample donor gender: M = Male, F = Female, U = Unknown), Age (sample donor chronological age in years; in the original datasets deposited on GEO, it can be either rounded by the researchers to full years, or converted from months, weeks, or days; where available, we calculated years from the smaller units), Condition (one of AACs or HC), and Class.

As there is no gold standard for DNAm processing, each research group carries out their preferred pipeline that does not necessarily match the processing pipeline used for training the clock model, especially in case of applying earlier clocks (e.g., those by Hannum et al. [15] or Horvath [8]) to recently collected data. Therefore, so as to retain this typical workflow and not to put any clock model into advantage by choosing the same processing that matches its own pipeline for every dataset, we did not perform any post-processing, inter-dataset normalization, or batch effect correction. In doing so, we also relied on two existing papers. First, compiling already pre-processed datasets without performing the same processing for all of them was done by Ying et al. [42] in creating Biolearn, another notable effort in the aging clock community. Second, we were encouraged by a recent work by Varshavsky et al. [28] who managed to create an accurate clock model by combining several blood datasets—without any additional normalization or correction procedure, using already pre-processed data from previous studies (some of which are included in our dataset as well), and thus demonstrating that the between-dataset normalization is not critical for this type of data.

A.11 Benchmarking results without FDR correction

Figures A4 and A5 demonstrate benchmarking results before applying FDR correction.

Name	Dataset ID	Platform	Tissue	Class	Condition	N samples	Age distribution
Reynolds, 2014	GSE56046	450K	B	CVD	AS	339 / 789	
Reynolds, 2014	GSE56581	450K	B	CVD	AS	66 / 133	
Nazarenko, 2014	GSE62867	27K	B	CVD	IHD	6	
Soriano-Tárraga, 2016	GSE69138	450K	B	CVD	CVA	185	
Istas, 2017	GSE107143	450K	B	CVD	AS	8	
Cullell, 2022	GSE203399	850K, 450K	B	CVD	CVA	121	
Harris, 2012	GSE32148	450K	B	ISD	IBD	19 / 27	
Horvath, 2015a	GSE53840	450K	B	ISD	HIV	111	
Horvath, 2015a	GSE53841	450K	B	ISD	HIV	24	
Gross, 2016	GSE67705	450K	B	ISD	HIV	91 / 189	
Horvath, 2015a	GSE67751	450K	B	ISD	HIV	69 / 23	
Zhang, 2016	GSE77696	450K	B	ISD	HIV	117 / 261	
Li Yim, 2016	GSE81961	450K	B	ISD	IBD	22 / 15	
Ventham, 2016	GSE87640	450K	B	ISD	IBD	84 / 156	
Ventham, 2016	GSE87648	450K	B	ISD	IBD	178 / 204	
Zhang, 2017	GSE100264	450K	B	ISD	HIV	386	
Zhang, 2017	GSE107080	850K	B	ISD	HIV	405	
Zhang, 2018	GSE117859	450K	B	ISD	HIV	608	
Zhang, 2018	GSE117860	850K	B	ISD	HIV	529	
Oriol-Tordera, 2020	GSE140800	450K	B	ISD	HIV	70	
Martinez-Picado, 2023	GSE143942	450K	B	ISD	HIV	12 / 42	
DiNardo, 2020	GSE145714	850K	B	ISD	HIV+TB	10 / 8	
Oriol-Tordera, 2022	GSE185389	450K	B	ISD	HIV	56	
Oriol-Tordera, 2022	GSE185390	850K	B	ISD	HIV	30	
Esteban-Cantos, 2023	GSE217633	850K	B	ISD	HIV	43 / 368	
Day, 2013	GSE49909	27K	B	MBD	XOB	40 / 9	
Rakyan, 2011	GSE56606	27K	B	MBD	T1D	53 / 29	
Lunnon, 2015	GSE62003	450K	B	MBD	T2D	58	
Ramos-Molina, 2019	GSE131461	850K	B	MBD	XOB	20	
Nonino, 2021	GSE166611	450K	B	MBD	XOB	17 / 17	
Noronha, 2022	GSE193836	450K	B	MBD	XOB	11 / 11	
Liu, 2013	GSE42861	450K	B	MSD	RA	335 / 354	
Guo, 2017	GSE71841	450K	B	MSD	RA	12 / 12	
Fernandez-Rebollo, 2018	GSE99624	450K	B	MSD	OP	16 / 52	
Rhead, 2017	GSE131989	450K	B	MSD	RA	123 / 230	
Rodríguez-Ubreva, 2019	GSE134429	850K	B	MSD	RA	17 / 17	
Clark, 2020	GSE137593	850K	B	MSD	RA	32	
Clark, 2020	GSE137594	850K	B	MSD	RA	31	
Tao, 2021	GSE138653	850K	B	MSD	RA	80	
de la Calle-Fabregat, 2021	GSE175364	850K, 450K	B	MSD	RA	13 / 8	
Julià, 2022	GSE176168	850K	B	MSD	RA	113	
Chen, 2023	GSE228104	850K	B	MSD	RA	40	
Marabita, 2013	GSE43976	450K	B	NDD	MS	52	
Lunnon, 2014	GSE59685	450K	B	NDD	AD	9 / 48	
Horvath, 2015b	GSE72774	450K	B	NDD	PD	219 / 289	
Horvath, 2015b	GSE72776	450K	B	NDD	PD	38 / 46	
Castro, 2019	GSE103929	450K	B	NDD	MS	49	
Kular, 2019	GSE106648	450K	B	NDD	MS	138 / 140	
Chuang, 2017	GSE111223	450K	S	NDD	PD	131 / 131	
Chuang, 2019	GSE111629	450K	B	NDD	PD	237 / 335	
Ntranos, 2019	GSE112596	850K	B	NDD	MS	112	
Ezquerra, 2023	GSE122244	850K	B	NDD	PD	34 / 35	
Ewing, 2019	GSE130029	450K	B	NDD	MS	11 / 20	
Ewing, 2019	GSE130030	450K	B	NDD	MS	14 / 14	
Carlström, 2019	GSE130491	850K	B	NDD	MS	82	
Roubroeks, 2020	GSE144858	450K	B	NDD	AD	96 / 93	
Go, 2020	GSE151355	450K	B	NDD	PD	20	
Dabin, 2020	GSE156994	450K	B	NDD	CJD	103 / 114	
Bingen, 2023	GSE219293	850K	B	NDD	MS	18 / 29	
Esterhuyse, 2015	GSE72338	450K	B	RSD	TB	20 / 10	
Chen, 2021	GSE118468	450K	B	RSD	COPD	9 / 15	
Chen, 2020	GSE118469	450K	B	RSD	TB	6 / 12	
DiNardo, 2020	GSE145714	850K	B	RSD	TB	10 / 14	
Maierhofer, 2019	GSE131752	850K	B	PGS	WS	24 / 21	
Bejaoui, 2022	GSE182991	850K	B	PGS	HGPS	13 / 15	
Qannan, 2022	GSE214297	850K	B	PGS	CGL	9	

Condition classes included in the benchmarking dataset

HC   CVD   ISD   MBD   MSD   NDD   RSD   PGS

Figure A2: Descriptive statistics of datasets included in the benchmark. B: blood, S: saliva. Ages are indicated in years.

| Name	Dataset ID	Platform	Tissue	Class	Condition	N samples	Age distribution
Athanasios, 2012	GSE40005	450K	B	HC	HC	12	
Tsaprouni, 2014	GSE50660	450K	B	HC	HC	464	
Demetriou, 2013	GSE51057	450K	B	HC	HC	177	
Zhang, 2015	GSE51388	450K	B	HC	HC	60	
Bell, 2014	GSE53128	450K	B	HC	HC	43	
Li, 2014	GSE53740	450K	B	HC	HC	193	
McRae, 2014	GSE56105	450K	B	HC	HC	614	
Tserel, 2015	GSE59065	450K	B	HC	HC	296	
Flanagan, 2015	GSE61151	450K	B	HC	HC	184	
Xu, 2015	GSE65638	450K	B	HC	HC	16	
Tabassum, 2015	GSE67490	450K	B	HC	HC	36	
Horvath, 2016	GSE72773	450K	B	HC	HC	310	
Horvath, 2016	GSE72777	450K	B	HC	HC	46	
Kok, 2015	GSE74548	450K	B	HC	HC	86	
Houtepen, 2016	GSE77445	450K	B	HC	HC	85	
Tobi, 2018	GSE78743	450K	B	HC	HC	16	
Hannon, 2016	GSE80417	450K	B	HC	HC	305	
Martens, 2020	GSE85311	450K	B	HC	HC	38	
Roos, 2016	GSE89093	450K	B	HC	HC	46	
Joseph, 2019	GSE96879	450K	B	HC	HC	33	
Salas, 2018	GSE110554	850K	B	HC	HC	37	
Chen, 2018	GSE112696	450K	B	HC	HC	6	
Cobben, 2019	GSE112987	450K	B	HC	HC	64	
Crawford, 2018	GSE113725	450K	B	HC	HC	48	
Boks, 2018	GSE116378	450K	B	HC	HC	49	
Boks, 2018	GSE116379	450K	B	HC	HC	79	
Córdova-Palomera, 2018	GSE120307	450K	B	HC	HC	20	
Zaimi, 2018	GSE123914	850K	B	HC	HC	69	
Arloth, 2020	GSE125105	450K	B	HC	HC	210	
Zannas, 2019	GSE128235	450K	B	HC	HC	208	
Bartlett, 2019	GSE130748	850K	B	HC	HC	37	
Johnson, 2020	GSE142512	850K, 450K	B	HC	HC	199	
Westerman, 2020	GSE143307	850K	B	HC	HC	24	
Vyas, 2020	GSE145254	850K	B	HC	HC	12	
Robinson, 2020	GSE147740	850K	B	HC	HC	1024	
Hannon, 2021	GSE152026	850K	B	HC	HC	519	
Konigsberg, 2021	GSE167202	850K	B	HC	HC	296	
Xu, 2021	GSE174422	450K	B	HC	HC	256	
Balnis, 2021	GSE174818	850K	B	HC	HC	26	
Barturen, 2022	GSE179325	850K	B	HC	HC	101	
Roy, 2021	GSE184269	850K	B	HC	HC	167	
Webster, 2024	GSE196696	850K	B	HC	HC	570	
Xiu, 2022	GSE201287	450K	B	HC	HC	40	
Clement, 2022	GSE210245	850K	B	HC	HC	18	
Kalyakulina, 2023	GSE234461	850K	B	HC	HC	245	
Owen, 2023	GSE235717	850K	B	HC	HC	35	

Figure A3: Descriptive statistics of datasets included in the training subset. B: blood. Ages are indicated in years.

Model	CVD	ISD	MBD	MSD	NDD	PGS	RSD	Total
PhenoAgeV2	0/3	7/10	0/4	4/6	6/12	1/3	3/4	21/42
GrimAgeV2	0/3	7/10	0/4	3/6	2/12	2/3	3/4	17/42
GrimAgeV1	0/3	7/10	0/4	3/6	2/12	2/3	2/4	16/42
PhenoAgeV1	0/3	6/10	0/4	2/6	1/12	1/3	1/4	11/42
YingAdaptAge	0/3	6/10	0/4	1/6	1/12	2/3	0/4	10/42
Lin	0/3	7/10	0/4	0/6	1/12	0/3	1/4	9/42
YingCausAge	0/3	4/10	0/4	1/6	1/12	2/3	0/4	8/42
HorvathV2	0/3	4/10	0/4	0/6	2/12	2/3	0/4	8/42
VidalBralo	0/3	5/10	0/4	1/6	0/12	1/3	0/4	7/42
HorvathV1	0/3	5/10	0/4	0/6	0/12	1/3	0/4	6/42
Hannum	0/3	3/10	0/4	1/6	1/12	1/3	0/4	6/42
YingDamAge	0/3	3/10	0/4	0/6	1/12	1/3	0/4	5/42
Zhang19_EN	0/3	2/10	0/4	0/6	0/12	1/3	0/4	3/42

Figure A4: AA2 task results split into columns by condition class **without FDR correction of P-values**. Scores demonstrate the number of datasets per class, in which a given clock model detected significant (at the 0.05 level of significance) difference between the HC and AAC cohorts.

Model	CVD	ISD	MBD	MSD	NDD	Total
GrimAgeV2	3/3	9/9	2/2	2/5	4/5	20/24
Zhang19_EN	0/3	9/9	1/2	5/5	4/5	19/24
Hannum	1/3	9/9	2/2	2/5	4/5	18/24
GrimAgeV1	1/3	9/9	2/2	2/5	2/5	16/24
VidalBralo	1/3	9/9	1/2	1/5	1/5	13/24
HorvathV2	0/3	9/9	0/2	0/5	3/5	12/24
HorvathV1	0/3	7/9	1/2	2/5	2/5	12/24
YingAdaptAge	1/3	4/9	1/2	2/5	3/5	11/24
PhenoAgeV2	0/3	6/9	1/2	2/5	1/5	10/24
Lin	0/3	8/9	0/2	0/5	1/5	9/24
PhenoAgeV1	0/3	6/9	0/2	0/5	1/5	7/24
YingDamAge	0/3	5/9	1/2	0/5	0/5	6/24
YingCausAge	0/3	2/9	0/2	1/5	0/5	3/24

Figure A5: AA1 task results **without FDR correction of P-values**: same as Figure A4, but the statistics are calculated for datasets containing the AAC cohort only.